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Shrm4, a protein expressed only in polarized tissues, is encoded by the KIAA1202 gene,
whose mutations have been linked to epilepsy and intellectual disability. However,
a physiological role for Shrm4 in the brain is yet to be established. Here, we report that Shrm4
is localized to synapses where it regulates dendritic spine morphology and interacts with the
C terminus of GABAB receptors (GABABRs) to control their cell surface expression and
intracellular trafficking via a dynein-dependent mechanism. Knockdown of Shrm4 in rat
severely impairs GABABR activity causing increased anxiety-like behaviour and susceptibility
to seizures. Moreover, Shrm4 influences hippocampal excitability by modulating tonic
inhibition in dentate gyrus granule cells, in a process involving crosstalk between GABABRs
and extrasynaptic d-subunit-containing GABAARs. Our data highlights a role for Shrm4 in
synaptogenesis and in maintaining GABABR-mediated inhibition, perturbation of which may
be responsible for the involvement of Shrm4 in cognitive disorders and epilepsy.
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T
he actin-binding proteins Shroom (Shrm) play an impor-
tant role in cytoskeletal organization and consist of
an N-terminal PDZ domain, a central Apx/Shrm Domain
1 (ASD1) and a C-terminal ASD2 domain1. There are four
evolutionarily conserved Shrm proteins (Shrm1-4)2 that are
localized to polarized tissues, including neurons1,3. Of these, only
Shrm4 lacks the actin-targeting ASD1 motif, and the role of its
PDZ domain is unknown. Murine Shrm4 possesses putative
binding sites for EVH1 (poly-proline rich domain), a PDZ (SNF)
binding motif4 and a stretch of glutamine and glutamate residues
preceding the C-terminal ASD2 motif that is unique to Shrm4,
but not other family members4. Shrm4 is ubiquitously expressed
throughout embryonic and adult murine brains2 and also binds
to F-actin in non-neuronal cells4.
The importance of Shrm4 is illustrated by two de novo
balanced X-chromosomal translocations, which disrupts the
KIAA1202 gene (Xp11.2) that encodes for Shrm4. In addition, a
pathogenic missense mutation was identified in an unrelated
large family, with carriers exhibiting mild-to-severe intellectual
disability (ID) and increased susceptibility to seizures2,5. Recent
studies reinforce the role of Shrm4 in ID6–8, however, how
disruption of KIAA1202 causes these neuropathological
conditions is unknown. Indeed, the role of Shrm4 in the brain
is also unknown, but given the pathological profile, it may regu-
late GABA-mediated inhibition9,10. GABA activates ionotropic
GABAA (ref. 11) (GABAAR) and metabotropic GABAB receptors
(GABABRs)12 to control inhibition which is important for
synaptic plasticity13,14. The importance of these receptors is
emphasized during dysfunction, which occurs in different
neurological disease14,15.
Here, we report that Shrm4 interacts with GABABRs to
facilitate trafficking to dendrites using a dynein-dependent
mechanism. For cell surface expression, GABABRs are obli-
gate heterodimers comprising GABABR1 (GABAB1) and R2
(GABAB2) subunits that mediate long-lasting synaptic inhibi-
tion16. However, the motor-protein-dependent trafficking of
these receptors is not fully understood.
We found that loss of Shrm4 compromises GABABR delivery
to postsynaptic compartments, impairs GABABR-mediated Kþ
currents and GABAAR-mediated tonic inhibition in the hippo-
campus, and reduces dendritic spine density altering the
composition of synaptic proteins resulting in increased anxiety-
like behaviour and susceptibility to seizures in rats. Our study
suggests a possible underlying mechanism by which Shrm4 may
be involved in epilepsy and ID.
Results
Shrm4 is an interacting partner of GABAB receptors. We first
investigated the subcellular localization of Shrm4 in cultured rat
hippocampal neurons at 18 days in vitro (DIV) by immunos-
taining and found colocalization with presynaptic (Bassoon) and
postsynaptic markers of excitatory (PSD-95) and inhibitory
(GABAAb3) synapses (Supplementary Fig. 1a). By using electron
microscopy and post-embedding immunogold methods with an
anti-Shrm4 antibody2, gold nanoparticles were identified in pre-
and post-synaptic areas and along dendrites (Supplementary
Fig. 1b; Supplementary Table 1). Biochemical fractionation of
adult rat brain hippocampi and cortices revealed enrichment of
Shrm4 in the postsynaptic density (PSD) fraction further confir-
ming its presence at synapses (Supplementary Fig. 1c).
To explore the role(s) of Shrm4 in neurons, we searched for
binding partners using yeast two-hybrid (Y2H) screening. The
PDZ domain of Shrm4 (residues 1–91; Fig. 1a) was selected as the
bait to screen against an adult human brain cDNA library, as this
domain participates in protein–protein interactions. Twenty
positive cDNA clones were isolated; six of these encoded a 100
amino acids stretch of the C-terminal tail of GABAB1 present in
both splice variants B1a and B1b, which differ by the inclusion
of two Sushi domains in the N terminus only in GABAB1a
(refs 12,14) (Fig. 1a). The interaction between Shrm4 and the
GABAB1 C-tail was crucially reliant on the Shrm4-PDZ domain
(PDZ domain 1–91: þ þ þ ; DPDZ 91–1,492: negative; DASD2
1–1,213: þ þ þ ; Fig. 1a). We confirmed this interaction
using rat brain lysates and found that endogenous Shrm4
co-precipitates with GABAB1a/b (Fig. 1b). GABABR antibody
specificity was confirmed by western blots from GABAB1a and
GABAB1b knockout mice17 (Supplementary Fig. 1d). Moreover,
direct stochastic optical reconstruction microscopy (dSTORM) of
14DIV hippocampal neurons revealed that Shrm4 and GABABRs
co-cluster in neurons (Fig. 1c; Supplementary Fig. 1e)18.
GST pull-downs from cultured hippocampal neurons and
brain extracts confirmed that Shrm4-PDZ domain alone is
sufficient to precipitate GABAB1a/b, unlike a mutated Shrm4-PDZ
domain (K26G27/AA) (Fig. 1d, panels 1–3). To ensure GABAB1
specificity for this interaction, we verified that HA-tagged Shrm4
did not co-precipitate Flag-tagged GABAB2 from HEK293 cells
when transfected alone (Fig. 1e).
We used immunoprecipitation to determine the minimal
region of the GABAB1 C-tail that interacts with Shrm4 in
HEK293 cells expressing Shrm4-GFP, GABAB2 and GABAB1a
cDNAs with differing C termini (Fig. 1f). This revealed that
R859LITRGEWQSEA870 in the C-tail of GABAB1 interacted with
the Shrm4-PDZ domain (Fig. 1f). To confirm this interaction, we
produced a cell-permeable peptide fragment (Tat-peptide) enco-
mpassing the Shrm4-GABAB1 binding site on GABAB1
(859–870). We verified the efficiency of this peptide in pull-
down experiments with GST-PDZ incubating different concen-
tration of Tat control or Tat-859–870 with lysates of HEK293
cells overexpressing GABAB1a-GFP and GABAB2 (Supplementary
Fig. 1f) and a dose-dependence was observed. We then incubated
lysates from HEK293 cells overexpressing GABAB1a and GABAB2
with this peptide before GST pull-down using Shrm4-PDZ or its
mutant form (K26G27/AA). Consistent with previous results,
co-precipitation of GABAB1 was reduced after preincubation with
the Tat-peptide compared with its scrambled control (Fig. 1g).
These results reveal a new association between the PDZ domain
of Shrm4 and residues 859–870 of the GABAB1 C terminus.
Shrm4 regulates the surface expression of GABABRs. Given
that the C-tail of GABAB1 is important for trafficking to the cell
surface19,20, we next examined whether Shrm4 regulates GABABR
trafficking. We designed two shRNAs that specifically targeted rat
(shRNA#1 and #2) and human (shRNA#2) Shrm4 transcripts.
To test their effectiveness as Shrm4 silencers, HEK293 cells were
transfected with human HA-Shrm4 cDNA (Rescue) with or
without each shRNA. Both shRNAs reduced Shrm4 expression
while co-transfection of a rescue construct with shRNA#1
restored expression (Supplementary Fig. 2a,b). We extended
this approach to neurons, transfecting Scrambled, shRNA#1,
shRNA#2 or Rescue constructs at 8DIV for later analysis of
surface levels of GABAB1 at 18DIV. Interestingly, both shRNAs
reduced surface levels of GABAB1 that can be rescued by the
re-expression of Shrm4 (Fig. 1h, full neurons in Supplementary
Fig. 2c). As an additional control, we tested the effect of knocking
down Shrm3 and found no effect on GABAB1 surface expression
indicating a unique role played by Shrm4 in GABAB1 trafficking
(Supplementary Fig. 2d). We next used lentiviral delivery to
corroborate our immunostaining results. For this we used
cell surface biotinylation assays for GABABRs (Fig. 1i). Shrm4
knockdown reduced surface expression of GABABRs without
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affecting the total expression of GABABRs or the total and surface
expression of GABAAR a1 subunits used as negative controls
(Fig. 1i). Thus, Shrm4 is important for GABAB1 trafficking in
neurons.
Shrm4 regulates synaptic structure and protein composition.
Since Shrm4 colocalizes with PSD-95 and Bassoon, we investi-
gated if its knockdown affected excitatory synapses in rat
pyramidal hippocampal neurons. In these excitatory neurons,
expressing scrambled or shRNA#1 before synaptogenesis (8DIV)
did not alter the branching or dendritic diameters at 18DIV
(Fig. 2a). We therefore refined our analysis and studied dendritic
spines, where defects are commonly linked to ID21. First, we
investigated the expression levels of PSD-95, AMPA receptor
subunit GluA2 and presynaptic markers Bassoon and Synapsin,
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Figure 1 | Shrm4 interaction with GABABRs modulates cell surface expression. (a) Representations of Shrm4 and GABABR subunit 1a and 1b interacting
domains. The PDZ domain of Shrm4 (1–91 aa) was used as bait for Y2H screening on adult human brain cDNA library. Twenty positive clones were isolated;
six encoded for a 100 aa stretch of the GABABR subunit 1 C-terminal tail (both isoforms (1a and 1b)). The PDZ domain and DASD2 constructs interact with
the C-terminal tail of GABAB1 (þ þ þ ) while DPDZ truncated construct does not ( ). TMD: Transmembrane domains. (b) Co-immunoprecipitation
experiments on adult rat brain extracts using anti-Shrm4 antibody show Shrm4 and GABAB1 association (full blot in Supplementary Fig. 11). (c) (Left)
dSTORM imaging of GABABR (red) and Shrm4 (green) on 14DIV rat cultured hippocampal neurons. (Right) Shrm4 and GABABR puncta co-cluster as
evidenced by cross-correlation analysis. Error-bars are s.e.m.; number of regions¼ 29, number of fields¼ 3. Scale bar, 0.4mm. (d) GST pull-down
experiments on 18DIV rat cultured hippocampal neurons (1) and rat brain (2) extract show that Shrm4-PDZ domain (GST-PDZ; aas 1–91) pulls down both
GABAB1 isoforms whereas (3) mutant GST-PDZ (AA) does not (full blot in Supplementary Fig. 11). (e) Co-immunoprecipitation experiments on HEK293
cells expressing HA-Shrm4 and GABAB2-Flag, showing that Shrm4 does not associate with GABAB2 in absence of GABAB1 (full blot in Supplementary
Fig. 11). (f) Scheme of truncated GABABR constructs: deletion 1: D859–961; deletion 2: D922–961; and deletion 3: D870–961 with co-immunoprecipitation
results from HEK293 cells expressing Shrm4-GFP and each of the GABAB1a constructs. GFP-Shrm4 immunoprecipitates full-length GABAB1a, deletion 2,
and deletion 3, but not deletion 1 (full blot in Supplementary Fig. 11). (g) (Top) GST pull-down experiments using GST-PDZ or mutant GST-PDZ (AA) on
lysates of HEK293 cells overexpressing GABAB1 and GABAB2 incubated with Tat-control peptide or Tat-859–870 peptide corresponding to the previously
identified minimal GABAB1-Shrm4 binding region. (Bottom) Histograms showing GABAB1a mean intensity normalized to Tat-control peptide±s.e.m. n¼ 3;
**P¼0.046; t-test (full blot in Supplementary Fig. 11). (h) Surface immunostaining for GABABR in rat cultured hippocampal neurons at 18DIV transfected
with scrambled, shRNA#1, shRNA#2 or rescue constructs at 8DIV. Scale bar, 15 mm. Histograms show mean±s.e.m. n¼ 5–15, Scrambled versus shRNA#1
*P¼0.0153; Scrambled versus shRNA#2 *P¼0.0153; One-way ANOVA-Mann–Whitney. (i) GABABR cell surface biotinylation from 18DIV rat cultured
hippocampal neurons infected with scrambled#1 (Scr#1) or shRNA#1 (shRNA#1) at 8DIV and western blot. Shrm4 silencing reduces GABAB1 surface
expression, but does not change total signal for GABAB1 or surface (and total) signal for GABAAR a1 subunit. Histograms show mean±s.e.m.; n¼4;
**P¼0.0069; t-test (full blot in Supplementary Fig. 11).
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using immunofluorescence (Fig. 2b, full neurons shown in
Supplementary Fig. 3). The numbers and intensities of
fluorescent puncta for all four markers were reduced in
Shrm4-silenced neurons and rescued by HA-Shrm4 (Fig. 2c).
The decrease occurred in parallel with a reduction in spine
density and this was also rescued by HA-Shrm4 (Fig. 2d). These
results were replicated by silencing via shRNA#2 (Supplementary
Fig. 4a). Finally, to attribute these changes to Shrm4 specific
knockdown, we silenced Shrm3 and found no changes to
dendritic spine density as shown in Supplementary Fig. 2d.
Shrm4 silencing also had profound consequences on spine
morphology reducing spine length, without affecting spine
head width (Fig. 2e,f) while increasing the number of stubby
spines, compared with scrambled controls (Fig. 2g). These
effects were reversed using the rescue construct discounting
non-specific effects of the shRNA (Fig. 2e–g). Interestingly, no
changes in spine density were observed with Shrm4 knock-
down after synaptogenesis at 12DIV (Supplementary Fig. 4b)
suggesting a role for Shrm4 in synaptogenesis or in synapse
maintenance.
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Figure 2 | Shrm4 is key mediator of dendritic spine formation and morphology. (a) Sholl analyses were performed on 18DIV rat hippocampal neurons
transfected at 8DIV with GFP-coexpressing knockdown shRNA#1 or scrambled#1. No difference in dendritic arborization and diameter was observed
between the two conditions. Scale bars, 10mm. (b) Images of rat hippocampal neurons transfected at 8DIV with Shrm4 scrambled#1, shRNA#1 or rescue
constructs and immunostained for PSD-95, Bassoon, GluA2 and Synapsin post-synaptogenesis at 18DIV. Scale bar, 10mm. (c) Numbers of fluorescence
puncta/15mm dendrite (left panel) and mean fluorescence intensity of synaptic markers (right panel). The effect of Shrm4 silencing could be rescued by
coexpressing wild-type Shrm4 cDNA resistant to knockdown by shRNA#1 (Data normalized to scrambled#1 controls) Histograms show mean
±s.e.m.; see Supplementary Table 2 for statistical tests. (d) Normalized spine density per 20mm of hippocampal neurons transfected at 8DIV for Shrm4
knockdown and rescue. See Supplementary Table 2 for statistical tests. (e) Spine head width and (f) length for scrambled, knockdown and rescue
cells. See Supplementary Table 2 for statistical tests. (g) Percentages of mushroom, stubby and thin spines for scrambled, knockdown and rescue cells.
Histograms show mean ±s.e.m.; see Supplementary Table 2 for statistical tests. (h) (Left) Images of rat hippocampal neurons transfected at 8DIV with
scrambled, GABAB1 knockdown shRNA or rescue constructs and analysed at 18DIV. (Right) Histogram showing normalized spine density per 20mm of
hippocampal neurons transfected at 8DIV for scrambled, GABAB1 knockdown and rescue; Histograms show mean±s.e.m.; n¼6–8 cells; Scrambled versus
shRNA **P¼0.0056; shRNA versus rescue *P¼0.0108, one-way ANOVA-Mann–Whitney. Scale bars, 10mm. (i) (Left) Images of 17DIV rat hippocampal
neurons transfected at 5DIV with pSuper and treated from 8DIV to 13DIV with a Tat control or Tat-859–870 peptide. (Right) Histogram showing spine
density per 40mm dendrite of 17DIV-treated hippocampal neurons; n¼ 10; ***P¼0.0001; t-test. Scale bar, 10mm. (j) Representative Ca2þ signals from
hippocampal neurons expressing dsRed-coexpressing knockdown shRNA#1 or scrambled#1 along with GCaMP6 fast under basal conditions in modified
Krebs solution (in mM: 140 NaCl, 2.5 CaCl2, 4.7 KCl, 11 glucose, and 5 HEPES, pH 7.4. Scale bar, 5 mm. (k) Representative Ca2þ signals imaged from single
dendrites (grey) and averaged traces (black) using GCaMP6f. (l) Maximum and averaged DF/F0 values of Ca2þ signals in scrambled#1 and shRNA#1
condition. (m) Time course of averaged DF/F0 values and single exponential fits (red) of Ca2þ signals in scrambled#1 and shRNA#1 condition. (n) Mean
rise times and (o) decay t of Ca2þ signals in scrambled#1 and shRNA#1 condition n¼ 10–15; histograms are means±s.e.m. *Po0.05, **Po0.01,
***Po0.001; t-test.
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To assess whether Shrm4 silencing reduced the density
of spines via down-regulation of dendritic GABABRs, we trans-
fected hippocampal neurons with GABAB1 shRNA, or scrambled
shRNA22 or GABAB1 shRNA together with shRNA-insensitive
GABAB1b cDNA before synaptogenesis (8DIV), for processing
at 18DIV for immunofluorescence. GABAB1 knockdown reduced
GABAB1 immunofluorescence (Supplementary Fig. 5a), and
similar to Shrm4 silencing, also reduced the density of
spines, which was rescued by shRNA-insensitive GABAB1b
cDNA (Fig. 2h).
Then, we evaluated the specific involvement of Shrm4–
GABABRs interaction on spine density by applying the
Tat-859–870 peptide to hippocampal cultured neurons from
8DIV to 13DIV during the synaptogenesis peak. This treatment
was sufficient to induce a reduction in spine density similar to
that observed in Shrm4 or GABAB1 knockdown condition
demonstrating that the interaction between the two proteins is
necessary for normal spine development (Fig. 2i). Interestingly,
silencing of Shrm4 also resulted in changes in spontaneous
dendritic Ca2þ -signals (Fig. 2j,k), assessed using GCaMP6f,
without a change in mean amplitudes of spikes (Fig. 2l) in
hippocampal neurons. In particular, we observed slower rise
(Fig. 2m,n) and decay times (Fig. 2m,o) of Ca2þ transients
in Shrm4-knockdown neurons, which could have important
consequences for spine morphology. Moreover, these defects were
not rescued by the concomitant overexpression of GABAB1DC
mutant demonstrating the dependency of these effects on
GABABRs surface expression (Supplementary Fig 5b).
Thus, Shrm4 is localized at excitatory synapses and plays a
crucial role in determining the morphology and molecular
structure of dendritic spines most likely by modulating the
surface expression of GABAB1 receptors.
Shrm4 and GABAB1 are associated in a complex with DIC. As
Shrm4 knockdown reduced surface GABAB1 receptors without
affecting the total level of protein expression, we wondered
whether this occurred because of a trafficking impairment.
Immunostaining for GABAB1 in permeabilized hippocampal
neurons after Shrm4 knockdown revealed an increased intensity
of intracellular GABABR expression in the soma compared with
scrambled controls, indicating an accumulation in intracellular
compartments which could be reversed by the rescue construct
(Fig. 3a).
Accumulation of GABABRs in the soma in Shrm4-silenced
neurons could reflect increased internalization, or defective
transport from the soma to the cell surface, or both. To disti-
nguish, GABABR internalization was analysed in live hippo-
campal neurons23. These were transfected at 7DIV with cDNAs
encoding for GABAB1a tagged with a bungarotoxin (BTX)
binding site, and GABAB2, together with either knockdown or
scrambled shRNAs. No difference in GABABR internalization
rates between Shrm4-silenced neurons and control neurons were
found (Supplementary Fig. 6a–e).
As a consequence, we investigated the transport of GABABRs
to distal compartments, which should be driven by microtu-
bule-based motor proteins: kinesins and dyneins24. Kinesin-1
is responsible for GABAB1a transport through the axonal
endoplasmic reticulum (ER) and ER–Golgi intermediate
compartment (ERGIC25); while dynein targets GABAB1 to the
dendrites26.
Using anti-Shrm4 antibody in adult rat brain lysates, we co-
immunoprecipitated the dynein intermediate chain (DIC),
GABAB1 and GABAB2, but not any of KIF5 isoforms (Fig. 3b;
Supplementary Fig. 6f). We then confirmed the existence of this
complex in transfected HEK293 cells by immunoprecipitating
Shrm4 with Shrm4-V5, and either GABAB1a-myc or
GABAB1b-myc (Fig. 3c). Interestingly, DIC co-immunoprecipi-
tated with HA-Shrm4 even in the absence of GABAB1 suggesting
that these two proteins are associated in a molecular complex
(Fig. 3d).
We found histidine-tagged DIC associated with Shrm4-PDZ
domain also in pull-down experiment in vitro demonstrating that
the two proteins can interact (Fig. 3e). Of course, these results
cannot exclude other factors, such as dynein light chains, that
can participate in a Shrm4-DIC complex in vivo. Nevertheless, to
identify which domain of Shrm4 was responsible for the
interaction, we used a GST-tagged PDZ domain mutated in the
classical PDZ binding site (K26G27/AA). This mutant was still
able to pull-down histidine-tagged DIC in vitro (Fig. 3e)
suggesting that another region of the Shrm4-PDZ domain was
involved. The analysis of the Shrm4-PDZ solution structure
(Protein Data Bank (PDB) code: 2EDP) highlighted the
N-terminal segment (first 14 amino acids) as one of the portions
more likely involved in interaction with DIC. Indeed, this
segment of Shrm4-PDZ is solvent accessible and is opposite to the
PDZ region that participates in classic protein’s C-termini
recognition (b2–a2 interface27). We truncated 14 amino acids
at the N terminus of Shrm4-PDZ (GST-tagged PDZD14) and
found that eliminating these residues completely abolished DIC
binding in adult rat brain lysates (Fig. 3f). These results suggest
that Shrm4 has the ability to bind GABAB1 and DIC
simultaneously, forming a ternary complex. Using in silico
modelling, we propose a structure for this complex (Supple-
mentary Fig. 6g). Collectively, the results of in vitro experiments
suggest that the b1 and b2 strands of Shrm4 bind the R859
LITRGEWQSEA870 segment of GABAB1 and DIC, respectively.
By combining the information from our in vitro experiments with
the structure availability of the Shrm4-PDZ, DIC 110–138
fragment in complex with LCs, and the coil–coil C-terminal
heterodimer of GABAB1b and GABAB2 (PDB: 4PAS28), we
could predict a low resolution model of the Shrm4-PDZ in
complex with the GABAB1b–GABAB2 heterodimer, DIC and LC8
(Supplementary Fig. 6g).
By using dSTORM on 18DIV hippocampal neurons, we
detected Shrm4 puncta on tubulin-positive filaments (Fig. 3g)
along dendrites where Shrm4 could associate with DIC and
GABAB1.
Finally, to ascertain if Shrm4, DIC and GABABRs associate
in a physiological context, we generated adeno-associated
virus serotype 5 (AAV5) expressing either scrambled (AAV5-
scrambled#1) or Shrm4 knockdown (AAV5-shRNA#1) shRNAs
and injected these into rat CA1 hippocampi (Fig. 3h).
Using western blots, the AAV5-knockdown-injected hemisphere
exhibited markedly lower Shrm4 protein levels than the
AAV5-scrambled-injected hemisphere (Supplementary Fig. 6h).
Subsequent anti-DIC immunoprecipitation from hippocampal
lysates, previously injected with either AAV5-scrambled#1 or
AAV5-shRNA#1, revealed co-immunoprecipitation of GABABR
with DIC in scrambled controls; however, this was significantly
reduced in lysates from the Shrm4-knockdown hemisphere
suggesting that dynein–GABABR co-association is dependent on
endogenous levels of Shrm4 (Fig. 3i). Taken together, these results
highlight the central role played by Shrm4 in the association of
dynein and GABABRs in the hippocampus.
Shrm4 mediates GABABR dynein-dependent dendritic transport.
As dynein transports postsynaptic proteins and Golgi outposts29,
and since Shrm4 orchestrates GABABR–dynein interaction, we
postulated that Shrm4 could mediate the dynein-dependent
GABABR trafficking to dendrites. To investigate, we analysed the
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distribution of endogenous GABABRs in the dendrites and axons
of 8DIV hippocampal neurons expressing: GFP (control), GFP-
coexpressing knockdown shRNA#1 either with or without rescue-
shRNA, and a GFP-tagged dominant-negative dynactin construct
(GFP-p150-cc1) that inhibits dynein activity30.
GABABR fluorescence intensity in dendrites of GFP-
shRNA#1 and GFP-p150-cc1-expressing neurons was markedly
lower compared with GFP controls (Fig. 4a), while fluorescence
in axons was unaffected (P40.05). Expressing the rescue
construct in Shrm4-silenced neurons recovered the GABABR
fluorescence in dendrites (Fig. 4a). We also quantified the
polarity index (PI), which has a higher value the greater
the abundance of receptors in dendrites (Fig. 4a, full neurons
are shown in Supplementary Fig. 7a). Interestingly, by
expressing shRNA#1 in neurons at 12DIV, the PI was signi-
ficantly lower compared with controls, suggesting that Shrm4 is
important for the normal abundance of dendritic GABABRs not
only before, but also after synaptogenesis (Supplementary
Fig. 7b). Finally, a second GFP-Shrm4 knockdown construct
(shRNA#2) also reduced the GABABR PI as shown in Supple-
mentary Fig. 4a.
Since both GABAB1a and GABAB1b are present in dendrites31,
we considered if Shrm4 knockdown or dynein inhibition
differentially modified their intracellular transport. Then we
expressed shRNA#1 or GFP-p150-cc1 that significantly reduced
the PI of expressed GABAB1a and GABAB1b subunits, consistent
with the reduced intensity noted for endogenous GABABRs
(Fig. 4b, full neurons are shown in Supplementary Fig. 8a).
Importantly, these results demonstrate that Shrm4 acts through
dynein to drive GABABRs to dendrites in hippocampal neurons
and overexpression of GABAB1a or GABAB1b does not rescue the
reduction in PI.
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Figure 3 | Shrm4 links GABABRs to the dynein/dynactin complex. (a) Immunofluorescence of GABABR intensity in the cell body of 18DIV cultured
hippocampal neurons transfected with Shrm4 scrambled#1, knockdown (shRNA#1) or rescue constructs at 8DIV. All data in bar graphs throughout
are means±s.e.m.; n¼ 10, 10, 15 *P¼0.0057; F(2,32)¼ 6.094, one-way ANOVA-Mann–Whitney. (b) Co-immunoprecipitation experiments on brain
extracts using polyclonal anti-Shrm4 show that Shrm4, GABAB1, GABAB2 and DIC are associated. By contrast, KIF5A is not present in this complex.
(c) Co-immunoprecipitation of both GABAB1 isoforms in HEK293 cells transfected with Shrm4-V5 and GABAB1a-myc (top) or GABAB1b-myc (bottom).
GABAB1a, GABAB1b and the endogenous DIC co-immunoprecipitated with Shrm4-V5. (d) Endogenous DIC co-immunoprecipitates with expressed HA-
Shrm4 in HEK293 cells in the absence of GABAB1a or GABAB1b subunits. Monoclonal antibodies (anti-V5, anti-myc and anti-DIC) were used for western
blot. (e) Western blot from in vitro pull-down assay of purified Histidine-tagged DIC using GST-PDZ and mutant GST-PDZ (AA). The Shrm4-PDZ domain is
able to directly bind DIC even when its common binding site is mutated. Ponceau Red staining of the blot has been presented at the bottom. (f) GSTpull-
down experiments on brain extracts show that the Shrm4-PDZ domain pulls down DIC while the mutant GST-PDZD14 does not. Ponceau red staining of the
blot has been presented at the bottom (full blot in Supplementary Fig. 11). (g) Conventional (top left) and super-resolution direct stochastic optical
reconstruction microscopy (dSTORM) (bottom left) imaging of Tubulin-ATTO 488 (shown in red) and Shrm4-Alexa 647 (shown in green). Shrm4 positive
puncta are localized along microtubule-positive filaments, as evidenced in the details of the super-resolution image (top right). The super-resolution data
has been quantified by cross-correlation analysis. The positive, higher than 1 cross-correlation, indicates co-clustering of the two fluorescent signals (Error-
bars are s.e.m.s, number of regions for the cross-correlation measurement: 30, number of fields: 3. Scale bar, 0.4 mm). (h) Schematic illustrating unilateral
local injection of AAV5-scrambled#1 (left hemisphere) and AAV5-shRNA#1 (right hemisphere) into rat brain CA1 hippocampus, with time line for recovery
and experiments. (i) Western blots and histograms showing monoclonal anti-DIC immunoprecipitation from scrambled and shRNA lysates of infected
hippocampus extracts (n¼ 6 rats). Co-precipitated GABAB1 levels were normalized to DIC immunoprecipitation levels and the normalized percentage of
GABAB1 co-precipitation was calculated. Histograms show mean±s.e.m.; *Po0.05, t-test.
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Furthermore, we verified that Shrm4 knockdown was not
altering GABAB1–GABAB2 dimerization32. We therefore co-
transfected GABAB1-myc and GABAB2-flag with either shRNA#1
or its scrambled control. This was followed by immunostaining for
the receptors. The analysis revealed high correlation in both
scrambled and Shrm4-knockdown conditions excluding
dysfunctional receptor dimerization (Supplementary Fig. 8b).
To address whether the reduction in dendritic GABABRs was a
consequence of decreased transport, fluorescence recovery after
photobleaching (FRAP) was applied to cultured hippocampal
neurons coexpressing GABAB1-RFP with GFP-shRNA#1 or GFP-
p150-cc1. For both, fluorescence recovery of GABAB1-RFP was
significantly delayed compared with neurons expressing the GFP
control. Only an increased half-time for fluorescence recovery,
without affecting the mobile fraction (plateau reached after 350 s),
was observed in Shrm4-silenced and GFP-p150-cc1-expressing
neurons, suggesting that transport of dendritic receptors,
occurring either intracellularly or at the surface level, was severely
impaired (Fig. 4c).
These results suggest that Shrm4 mediates dendritic transport
of the GABABRs heterodimer via its interaction with GABAB1
and DIC.
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Figure 4 | Association of Shrm4 with dynein/dynactin drives GABABRs dendritic transport. (a) Images of dendrites (d) and axons (ax) of hippocampal
neurons at 14DIV, transfected with GFP (control), knockdown (shRNA#1), rescue, or GFP-p150-cc1 at 8DIV. The mean fluorescence intensities of GABABRs are
shown with a polarity index (PI¼ (Id Ia)/(Idþ Ia)). For uniformly distribution PI¼0, whereas for dendritic polarization PI40, and for axonic polarization
PIo0. GABABR immunostaining was reduced in dendrites in knockdown and GFP-p150-cc1-expressing neurons compared with those for control and rescue
neurons (Left histograms, n¼ 10, 10, 15, 10; ***Po0.0001; F(3,41)¼ 21.91; one-way ANOVA-Mann–Whitney). In addition, the mean PI of shRNA#1- and
GFP-p150-cc1-expressing neurons is also reduced (right histograms, n¼ 10, 10, 15, 10; ***Po0.0001; F(3,41)¼ 14.72; One-way ANOVA-Mann–Whitney).
Scale bar, 10mm. (b) Images, mean fluorescences and PIs for dendrites (d) and axons (ax) of 14DIV hippocampal neurons co-transfected with GFP (control),
knockdown- (shRNA#1) or GFP-p150-cc1 together with either GABAB1a-myc or GABAB1b-myc at 8DIV. GABAB1 was detected with anti-myc and brevican
identified the axons. Histograms show mean±s.e.m.; GabaB1a: n¼ 10–15; ***Po0.0001; F(2,27)¼49.75; one-way ANOVA-Mann–Whitney; GABAB1b:
n¼ 10–15; ***P¼0.0001; F(2, 27)¼ 12.53; one-way ANOVA-Mann–Whitney. Scale bar, 10mm. (c) Fluorescence recovery after photobleaching (FRAP) of
cultured hippocampal neurons expressing GABAB1-RFP together with GFP, shRNA#1 or GFP-p150-cc1. The mean half-time (t1/2) for fluorescence recovery
(fluorescent recovery post-bleach corrected to 0%) is significantly longer in knockdown and GFP-p150-cc1-expressing neurons than GFP control. Histograms
show mean±s.e.m.; n¼ 7; ***P¼0.0002; F(2,15)¼ 16.43; one-way ANOVA-Mann–Whitney. (d) Whole-cell GIRK currents recorded in response to GABABR
activation by 10 (top) or 100 (bottom) mM baclofen, from rat hippocampal neurons at 14DIV, transfected either with scrambled, knockdown (shRNA#1) or
GFP-p150-cc1 at 8DIV. Baclofen-activated (10 and 100mM) GIRK current densities in Shrm4-silenced, dynein-inhibited neurons and scrambled shRNA neurons
are shown. Histograms show mean±s.e.m.; 10mM: n¼ 10, 10, 11; ***P¼0.0003; F(2,28)¼ 10.96, one-way ANOVA-Mann–Whitney; 100mM: n¼ 10, 9, 12;
***P¼0007; F(2,28)¼ 9.466). (e) Schematic of injection of AAV5-scrambled#1 (or #2) and AAV5-shRNA#1 (or #2) into opposing CA1 areas of rat, with
time line for recovery and experiments. (f) Representative traces and histograms showing changes in GIRK and current densities (pA/pF) from CA1 pyramidal
neurons evoked by baclofen (100mM, horizontal bars) and blocked by the selective GABABR antagonist, CGP54626 (5mM). Histograms show mean±s.e.m.;
n¼ 10; (left histogram shRNA#1: *P¼0.0298; t-test; right histogram shRNA#2: *P¼0.0471, t-test).
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Physiological role of Shrm4 in vitro and in vivo. GABABRs
activate G protein-coupled inwardly-rectifying Kþ channels,
generating slow inhibitory postsynaptic currents (IPSCs)33. As
Shrm4 regulates GABABR dendritic cell surface number, we
examined Kþ currents induced by the GABABR agonist baclofen
(10–100 mM) on 14DIV hippocampal neurons transfected at
7DIV with either GFP-coexpressing knockdown shRNA#1 or
scrambled#1 or p150-cc1. Peak Kþ current densities (pA/pF)
were lower in Shrm4-silenced and dynein-inhibited neurons
compared with scrambled controls (Fig. 4d), consistent with
a reduced number of dendritic GABABRs. This reduced current
was reversed by expressing shRNA-insensitive Shrm4 (Supple-
mentary Fig. 9a). By contrast, Kþ currents activated by meta-
botropic glutamate receptors were unaffected by Shrm4 silencing
and dynein inhibition (Supplementary Fig. 9b). GABAAR-
mediated miniature IPSCs (mIPSCs) were also unaffected by
Shrm4 silencing (Supplementary Fig. 9c), indicating that Shrm4
and dynein/dynactin selectively regulate GABABR-mediated
responses.
To assess if Shrm4 silencing affected the neurophysiology of
GABABRs, we injected AAV5-scrambled (left hemisphere) and
AAV5-shRNA#1 (right hemisphere) into the hippocampal CA1
region of 3 months-old rats33 (Fig. 4e). Input/output currents
were measured to evaluate the basal excitatory transmission and
we did not observe any statistically significant difference between
the two conditions (Supplementary Fig. 10a). We also recorded
field excitatory postsynaptic potentials (fEPSPs) in the apical
dendritic layer of CA1 3 weeks later by inducing long-term
potentiation (LTP) or long-term depression (LTD) via Schaffer
collateral stimulation. LTP and LTD induction and maintenance
were unaffected (Supplementary Fig. 10b,c) consistent with the
unchanged PSD-95 intensity in brain slices from injected animals
(Supplementary Fig. 10d). The apparent contradiction with the
defect observed in dendritic spine number can be explained by
noting that these animals were injected at three months of age,
when the peak of synaptogenesis has passed. We
know that Shrm4 knockdown in mature neurons did not affect
spine number (Supplementary Fig. 5b), whereas it is still able to
impair GABAB1 trafficking (Supplementary Fig. 4b) as shown by
the decreased polarity index.
Whole-cell Kþ currents evoked by baclofen in the CA1 of
acute slices from injected animals were significantly reduced by
Shrm4 knockdown compared with scrambled controls (Fig. 4f).
The injection of AAV5-shRNA#2 induced similar reductions in
Kþ current confirming the specificity of our results. Thus, Shrm4
silencing reduces functional GABABR responses in vitro and
in vivo, in accord with a reduced number of surface dendritic
GABABRs.
Shrm4 silencing in vivo affects hippocampal tonic inhibition.
Recent evidence suggests that GABABR activation enhances the
conductance of extrasynaptic d subunit-containing GABAARs of
dentate gyrus granule cells (DGGCs)34–36. As Shrm4 silencing
reduced GABABR activity, we explored if this affected tonic
inhibition in DGGCs.
Animals were injected with AAV5-scrambled (left hemisphere)
and AAV5-knockdown (right hemisphere) shRNAs into the DG
(Fig. 5a). Whole-cell recordings 3 weeks later from DGGCs in
acute slices35,36 subject to scrambled shRNA revealed that GABA
(5 mM) increased the bicuculline-sensitive baseline current
and current noise variance (Fig. 5b). For cells expressing
Shrm4-shRNA#1, both current and noise variance were reduced
compared with controls (Fig. 5b). As tonic inhibition in DGGCs
relies on d subunit-containing GABAARs34 and can be regulated
by GABABRs, we considered whether the reduced tonic current
was a direct consequence of a reduction in surface GABABRs.
Repeating these experiments in the presence of the GABABR
antagonist CGP54628, showed similar reduction in tonic current
and noise variance evident in the knockdown condition without
CGP pre-treatment (Fig. 5c). These data suggested that reducing
cell surface GABABRs has no direct effect on tonic inhibition,
which is more likely due to an indirect impairment of d subunit-
containing GABAARs. This was confirmed using the agonist
THIP at d subunit-selective concentrations (3 mM) and as
expected, the mean current and noise variance were reduced in
DGGCs in the hemisphere carrying the Shrm4 knockdown
compared with the control hemisphere (Fig. 5d). To exclude
off-target effects of shRNA#1, we injected a second knockdown
construct, AAV5-shRNA#2, which produced identical effects on
THIP-induced currents (Fig. 5e). By contrast, GABAAR-mediated
mIPSCs in DGGCs were unaffected (Supplementary Fig. 10e),
indicating that Shrm4 specifically regulates d subunit-containing
GABAAR-mediated responses.
Interestingly, co-immunoprecipitation using brain extracts
and monoclonal anti-GABAAR d subunit revealed that GABABRs
and d-subunit-containing GABAARs co-associate. By contrast,
the synaptic GABAAR g2 subunit37 was absent (Fig. 5f). Thus,
by controlling postsynaptic GABABRs, Shrm4 is also able to
regulate tonic inhibition mediated by d subunit-containing
GABAARs.
In vivo Shrm4 silencing causes behavioural deficits. A role for
GABABRs in anxiety38 and epilepsy14,39 is well-known. GABA
transmission has been also linked to neurodevelopmental disor-
ders such as autism spectrum disorders (ASD)40,41. Furthermore,
GABABR agonist application has been proposed as therapeutic
strategy for social deficits, repetitive behaviours and other aspects
of ASD in different mouse models42. To understand if reducing
GABABR numbers and tonic inhibition by Shrm4 knockdown has
behavioural implications, we injected rats bilaterally with either
Shrm4 knockdown (AAV5-shRNA#1 or AAV5-shRNA#2),
or AAV5-scrambled shRNA (AAV5-scrambled#1 or AAV5-
scrambled#2) and extensively analysed the behaviour of these
animals (Fig. 6a). Locomotor activity of the injected animals was
unaffected allowing us to perform subsequent behavioural
analyses without locomotor bias (Fig. 6b).
The elevated plus maze (EPM) and the marble-burying test
measured anxiety levels43 whereas social behaviours were
evaluated in a three-chamber apparatus44 and in the tube test
for aggressivity45. AAV5-knockdown-shRNA-injected rats
(with either shRNA#1 or shRNA#2) exhibited increased anxiety
and impaired social behaviour (Fig. 6c–f). In the EPM, Shrm4-
knockdown rats made fewer open-arm entries (Fig. 6c) and spent
less time in open arms compared with AAV5-scrambled shRNA-
injected controls (Fig. 6c). The total number of arm entries
was unaffected by AAV5-knockdown-shRNA, confirming that
locomotion was unaffected.
In the marble-burying test, animals injected with AAV5-
shRNA#1 buried a higher number of marbles and spent less
time before burying compared with AAV5-scrambled controls
confirming an increased anxiety level (Fig. 6d). Social behaviours
of animals injected with AAV5-shRNA#1 were also found
impaired with reduced time spent close to a stranger naive
animal (Fig. 6e, sociability) and to a second new stranger animal
(Fig. 6e, social novelty) compared with AAV5-scrambled
controls. These animals also showed greater aggression in the
tube test in terms of percentage of wins versus the control-
injected animals (Fig. 6f).
We then assessed involvement of Shrm4’s deficiency in
epilepsy by pentylenetetrazole (PTZ) administration to evaluate
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seizure sensitivity46 and recorded electro-encephalograms (EEG)
to measure spontaneous electrical activity (Fig. 7a).
Electrical activity evaluated for 24 h in freely moving awake
animals showed a significant spontaneous spike activity in all
the AAV5-shRNA#1 injected rats compared with the AAV5-
scrambled#1 (Fig. 7b,c) suggesting an increased general
excitability.
In fact, following PTZ injections (i/p 45mg kg 1)46, the
latency to the first seizure was reduced and the seizure duration
was longer for knockdown shRNA-injected animals (Fig. 7d). The
severity of the response to PTZ was also increased with greater
number of tonic-clonic seizures (Fig. 7d). This indicates that
in vivo Shrm4 silencing in CA1 produces defects in anxiety, social
behaviour and susceptibility to seizures. Similar effects on seizure
susceptibility were obtained when we injected rats intraperi-
toneally with Tat-859–870 peptide administering PTZ 12 h after
(Fig. 7e,f) demonstrating that the disruption of Shrm4–GABABRs
interaction was responsible of these effects.
These phenotypes parallel the defects in GABABR trafficking
and transmission observed in vitro and in vivo in Shrm4-silenced
hippocampal neurons.
Discussion
Several neurodevelopmental IDs including autism and Fragile
X syndrome are characterized by a reduction of GABABR
expression levels47,48, and treatment with GABABR agonists have
been reported to improve susceptibility to seizures49 and social
and cognitive behaviour50–52. In this study, we have characterized
an interaction between the ID-linked protein Shrm4, GABABRs
and dynein motor protein. The disruption of this complex leads
to dysfunction of GABABRs cell surface targeting and subsequent
reduction of signalling efficacy, and this has interesting parallels
with these neurodevelopmental disorders.
We have characterized physiological roles for Shrm4 by
discovering a new interaction between its PDZ domain and the
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GABAB1 C terminus, a region important for GABABRs traffick-
ing19,20. Only one other PDZ domain-containing protein,
Mupp1, is known to interact with GABABRs, but its physio-
logical role remains unknown53. The localization of Shrm4
to microtubule-positive filaments in dendrites suggests its
interaction with GABABRs is potentially critical for delivering
these receptors to membrane-delimited signalling domains.
Consistent with this, using shRNA silencing to reduce Shrm4
levels we observed decreased GABABR in dendrites, causing their
accumulation in the soma. This most likely involved
dysfunctional GABABR transport to the dendrites, a process
driven by microtubule-based motor proteins: kinesins and
dyneins. In this regard, we found that Shrm4 directly binds the
dynein intermediate chain with a distinct portion of the PDZ
domain (that is, the b1 and b2 strands) allowing for the
simultaneous binding of Shrm4 with both GABAB1 and DIC. In
fact we found that GABABRs and the dynein intermediate chain
co-associate, and significantly, dynein inhibition reduced
GABABR transport to the dendrites, but had no effect on
trafficking into axons. Therefore, both dynein and Shrm4 are
required to target GABABRs to dendrites.
We know that Shrm4 can associate with both GABAB1a and
GABAB1b, and that Shrm4 silencing reduced the levels of both
isoforms in the dendrites. However, GABAB1a is preferentially
sorted to axons under physiological conditions31 being targeted
via its Sushi domains in pre-Golgi ER or ERGIC25. We surmised
that only GABAB1a subunits that escape axonal targeting in
pre-Golgi compartments can then associate with Shrm4 in the
Golgi to be re-directed (like GABAB1b) to dendrites54.
On the basis of this premise, we propose that Shrm4, similar to
the ID protein PQBP1, functions as an adaptor protein55
for intracellular trafficking of cargo, by binding the C termini
of GABAB1 and also dynein to target these receptors to dendrites.
This is further supported by our finding that in vivo Shrm4
silencing reduced the association between GABABRs and dynein
and differs from other post-translational modifications that
influence the kinetics and pharmacological properties of
GABABRs12.
Our biochemical and imaging data strongly suggest that Shrm4
and dynein play crucial roles in inhibitory transmission. Shrm4
silencing or dynein/dynactin inhibition specifically reduced
baclofen-activated Kþ currents due to dysfunctional GABABR
CA1 3 weeks Motor Anxiety 
Social 
Week 1 Week 2 
AAV-GFP-Scrambled (#1,#2)
AAV-GFP-shRNA (#1, #2) 
AAV-GFP-Scrambled (#1,#2) or 
AAV-GFP-shRNA (#1, #2) 
O
pe
n 
ar
m
 e
nt
rie
s 
(%
)
Ti
m
e 
sp
en
t i
n
th
e 
op
en
 a
rm
s 
(%
)
To
ta
l n
um
be
r o
f e
nt
rie
s 
Elevated plus maze
0
5
10
15
20
25
30
35
40
*
**
0
10
20
30
*
*
0
1
2
3
4
5
6
7
8
AAV5-scrambled#1
AAV5-shRNA#1 
AAV5-shRNA#2 
AAV5-scrambled#2 
H
or
iz
on
ta
l c
ou
nt
s
(no
. p
er 
30
 m
in)
Motor activity
Ve
rti
ca
l c
ou
nt
s
(no
. p
er 
30
 m
in)
 
0
1,000
2,000
3,000
4,000
0
500
1,000
1,500
5
0
1
2
3
4
Bu
rie
d 
m
ar
bl
es
 (n
o.)
 **
Marble burying
0
200
400
600
800
1,000
La
te
nc
y 
(s)
***
a b
c d
–1.0
–0.5
0.0
0.5
1.0
In
de
x 
(s)
 
Sociability
***
–1.0
–0.5
0.0
0.5
1.0
***
Social novelty
In
de
x 
(s)
 
e f Aggression
0
20
40
60
80
%
 o
f w
in
s
**
Aggression 
Bilateral injection 
Figure 6 | Shrm4 silencing in vivo increases anxiety and impaired social behaviours. (a) Experimental design for investigating behavioural effects of
Shrm4 silencing in rat hippocampal CA1. Rats were injected bilaterally with either AAV5-scrambled#1 (or #2) or AAV5-shRNA#1 (or #2) and tested
after 3 weeks. (b) No change in motor function in terms of total number of counts evaluated in an automated activity cage for 30min between Shrm4
knockdown or control animals. (c) A reduced number of open-arm entries and time spent in the open arms for Shrm4 knockdown; no difference in the
total number of entries (open-arm entries: Scrambled#1 versus shRNA#1: n¼ 12, 8; *P¼0.045; t-test; Scrambled#2 versus shRNA#2: n¼ 5, 5;
**P¼0.005; t-test) (time spent in the open arms: Scrambled#1 versus shRNA#1: n¼8, 8; *P¼0.0307; t-test; Scrambled#2 versus shRNA#2: n¼8, 8;
*P¼0.0133; t-test). (d) An increased number of marbles buried and a decreased latency to the first burial were observed in knockdown animals
(buried marbles: n¼ 11, 10; **P¼0.008; t-test) (latency: n¼ 10, 10; ***P¼0.0003; t-test). (e) In the sociability and social novelty test, a reduced
time close to stranger 1 in the sociability test and to stranger 2 in the social novelty test was observed in AAV5-shRNA#1 rats compared with
AAV5-scrambled#1 rats; (Sociability: n¼ 5, 5; ***Po0.0001; t-test; social novelty: n¼ 5, 5; ***P¼0.0002; t-test). All histograms were presented
as mean±s.e.m. (f) Tube test—AAV5-shRNA#1 rats showed a greater aggression compared with AAV5-scrambled#1 rats. n¼ 5; **P¼0.0041;
Fisher’s exact probability test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14536
10 NATURE COMMUNICATIONS | 8:14536 | DOI: 10.1038/ncomms14536 | www.nature.com/naturecommunications
trafficking and depletion of surface dendritic GABABRs without
affecting GABAAR-mediated mIPSCs and glutamate-mediated
Kþ currents.
Depleting postsynaptic GABABRs in vivo increased seizure
susceptibility, as noted for GABAB1 / knockout mice56; the
weaver mouse (with mutated GIRK2 channel), and the Girk2 /
null mouse, all of which are characterized by a significant loss
of GABABR-mediated inhibition53,57. Thus it is not surprising
that Shrm4 silencing, or the disruption of Shrm4–GABABRs
interaction, are associated with augmented neuronal excitability, as
showed by the increase in spontaneous spikes recorded by EEG
and in seizures susceptibility after PTZ injection.
GABABR involvement in anxiety-related disorders remains
unclear. While GABAB1 / knockouts show increased anxiety58,
mice lacking either GABAB1a or GABAB1b isoforms are not
anxious40, possibly due to isoform compensation. However,
hippocampal Shrm4 silencing was associated with anxiogenic
behaviour, and as this impairs trafficking of both GABABR
isoforms to dendrites, the increased anxiety is likely due to a
reduction in postsynaptic GABABR numbers. Social behaviours
also appeared to be impaired on Shrm4 knockdown; this is
not surprising since GABA transmission has been linked to
ASD symptoms40–42. In addition, down-regulating GABABRs by
Shrm4 silencing surprisingly affected tonic inhibition. We found
GABABRs and d subunit-containing GABAARs co-associated,
which is consistent with their extrasynaptic localization in
the molecular layer of the DG59,60. By silencing Shrm4,
tonic inhibition mediated by d subunit-containing GABAARs is
impaired, which could also contribute towards increased seizures,
a feature noted previously for Gabrd / mice61.
Defects in dendritic spine density and shape are established
pathological correlates of X-linked IDs21,62 and Shrm4 silencing,
before synaptogenesis, reduced spine density, length and affected
their pre- and postsynaptic molecular composition. Shrm4 binds
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F-actin and can influence actin remodelling in non-neuronal
cells4 and F-actin dynamic is crucial for synaptogenesis and spine
plasticity63,64. Although Shrm4 could regulate the spine cyto-
skeleton, this is considered unlikely because Shrm4 silencing after
maturation has no effect on spine morphology, even though
dendritic GABABR number were still reduced. This could explain
why LTP induction and stability was unaffected by Shrm4
knockdown and is consistent with the maintenance of LTP in
GABAB1b / knockout mice, indicating that postsynaptic
GABABRs are not affecting LTP induction31. The dendritic
spine defects might derive indirectly from impaired GABABR
trafficking caused by Shrm4 silencing. Indeed, GABABR silencing
before synaptogenesis, or the inhibition of Shrm4–GABAB
interaction with Tat-859–870, induced a similar reduction in
spine density. In addition, given GABABRs modulate dendritic
Ca2þ signals65, by inhibiting voltage-gated Ca2þ channels,
perturbation in Ca2þ signalling due to altered trafficking of
GABABRs could also underlie spine defects.
In conclusion, our data identify Shrm4 as an important protein
for synaptogenesis and for maintaining the inhibitory equilibrium
mediated by the GABABRs and extrasynaptic d subunit-contain-
ing GABAARs. The consequences of disrupting Shrm4 expression
are severe and manifest by increased anxiety, social behaviours
impairments and a predisposition towards epilepsy.
Methods
Animals. Experimental procedures were performed in accordance with the Eur-
opean Communities Council Directive (86/809/EEC) on the care and use of ani-
mals and the UK Animals (Scientific Procedures) Act 1986, and were approved by
the CNR Institute of Neuroscience.
cDNA, shRNA constructs and cell-permeable peptide. The human KIAA1202
open reading frame 1 was subcloned into: pcDNA4/V5-HisB (Invitrogen) to obtain
Shrm4-V5; pEGFP-C1 (Clontech) to obtain GFP-Shrm4; and pTL1-HA3 to
obtain HA-Shrm4 (gift from Vera Kalscheuer). Flag-tagged GABAB2, myc-tagged
full-length GABAB1a, GABAB1a-D859–961, GABAB1a-D922–961 and GABAB1a-
D870–961 were cloned into the pRK5 plasmid for expression in HEK293 cells to
identify the minimal GABAB1 sequence that interacts with Shrm4 (ref. 23).
pCl-myc-GABAB1a and pCl-myc-GABAB1b constructs were used to investigate
the distribution of GABAB1a and GABAB1b isoforms in cultured hippocampal
neurons20. GABAB1a-mRFP (generous gift by Andre´s Couve, University of Chile)
was used for fluorescent recovery after photobleaching (FRAP) experiments.
Twenty-one base-pair small hairpin RNA sequences or their scrambled controls
(shRNA#1—GCTCACGGTGTCGAAGATTGA (RAT-RESCUE) (nucleotides
22-45); shRNA#2—AGCAAAGGGAATCATTTAGTA (RATþHUMAN)
(nucleotides 3,221–3,241); shRNA#1 scrambled—GATTCTAGCCGGACGGTG
TAA and shRNA#2 scrambled—GGTATAAGCAACGTAATGAAT) were
subcloned into the vectors pLVTHM-GFP (shRNA#1 and shRNA#2 used in vitro
experiments) and pAAV-U6-ZsGreenGFP (shRNA#1; in vivo experiments)
(both from Penn Vector Core, Pennsylvania). The 21 base-pair sequences
of the small hairpin RNAs (shRNA GABAB1) for silencing GABAB1 subunits
was GAATCTGCTCCAAGTCTT and the scrambled sequence was GTGCTATTAC
CCGTACAT22.
Cell-permeable peptides (CPPs) were obtained from Primm (Italy) and China
Peptide (China) (Tat control: YGRKKRRQRRR-TETWGQRSIE; Tat-859–870:
YGRKKRRQRRR-ITRGEWQSET). Lyophilized CPPs were resuspended in sterile
deionized water and used at the final concentration of 10 mM for pull-down
treatments, 20 mM for hippocampal culture treatments whereas were administered
by intraperitoneal injection at 3 nmol g 1 in vivo66.
The GW1-GFP-p150-cc1 construct was kindly donated by Casper Hoogenraad
(Utrecht). GW1-GFP was used as control. For GST pull-down assays, the PDZ
domain (aa 1–91), PDZD14 (aa 1–14) and mutated PDZ (KG/AA) of Shrm4 were
subcloned into pGEX-4T-1 to create GST-PDZ, GST-PDZD14 and GST-PDZ
(MutAA), respectively. For Y2H screens, Shrm4 DNA corresponding to (aa)
91–1,492 (DPDZ), 1–91 (PDZ) and 1,213–1,492 (DASD2) were subcloned into the
pGBKT7 vector and used as bait. The His-tagged IC-2C (DIC) was kindly donated
by Andy Catling (New Orleans). The Shrm3 siRNA sequence has been used
previously67.
Cell cultures, transfection and lentiviral infection. HEK293 (Thermo Fisher
Scientific) cells at 50–70% confluence (24 h after plating) were transiently
transfected with cDNA expression constructs (0.5–1 mg DNA per well in optiMEM,
Invitrogen) using lipofectamine 2000 (Invitrogen) for 1 h in 5% CO2 at 37 C.
Transfected cells were washed twice with PBS and grown for 48 h in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin, before fixation for immunocytochemistry, lysis for
co-immunoprecipitation, or GST pull-down. The 293FT cell line was used to
generate lentivirus and was grown in 1% G418 antibiotic. Primary hippocampal
neurons were prepared from Wistar E18 rat brains68,69 and plated onto coverslips
coated with poly-D-lysine (0.25mgml 1) at 75,000 per well for immunochemistry,
or 300,000 per well for GST pull-down, co-immunoprecipitation and lentivirus
infection. Neurons were transfected or infected at 7–8DIV or 12–13DIV and
processed for experiments at 16–20DIV. For transfection, lipofectamine 2000
was used. Infection with Shrm4-shRNA or scrambled shRNA was performed as
described previously70.
Western blots. Proteins were transferred from gels onto nitrocellulose membranes
followed by incubation with the following primary antibodies at room temperature
for 2–3 h in 5% milk at the stated dilutions: Shrm4 (1:200, used previously4),
GFP (1:2,000, MBL International), GABAAa1 (1:1,000, Millipore), HA (1:1,000,
Invitrogen) and GABAB2 (1:1,000, gift of B.B.) KIF5A (1:1,000, Abcam), KIF5B
(1:1,000, gift of F. Navone71) and KIF5C (1:1,000, Abcam) (all raised in rabbit);
and: a-tubulin (1:40,000, Sigma), GABAB Receptor 1 (1:2,000, Abcam), GABAAd
subunits (1:500, ROCKLAND), V5 (1:1,000, Invitrogen), myc (1:2,000, MBL
International), Synaptophysin (1:500, NeuroMab), DIC (1:1,000, Abcam) (raised in
mouse); and GABAAg2 (1:1,000, Abcam) raised in guinea pig. After rinsing,
primary antibodies were revealed by incubation at room temperature for 1 h with
horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies (both
1:2,000 from GE Healthcare) and immunoreactive bands on blots were visualized
by enhanced chemiluminescence (GE Healthcare).
GST pull-down and immunoprecipitation. GST fusion proteins were prepared in
BL21 E. coli and purified using standard procedures. For co-immunoprecipitation,
HEK293 cells, cultured neurons or rat brain homogenates (homogenization buffer:
50mM TRIS–HCl, 200mM NaCl, 1mM EDTA, 1% NP40, 1% Triton X-100, pH
7.4, protease inhibitor cocktail) were centrifuged at 10,000g for 30min at 4 C, and
supernatants incubated with antibodies (see below) at 4 C overnight. Protein
A-agarose beads (GE Healthcare, USA) were then incubated with the supernatants
at 4 C for 2 h. Beads were washed three times with lysis buffer, resuspended in 3
sample buffer and after boiling for 5min, the resulting
solution was analysed by SDS–PAGE, followed by western blotting with antibodies
(see below).
For in vitro interaction assays, His-tagged DIC was expressed in E. coli BL21
strain and purified with a Protino Ni-Ted Kit (Macherey-Nagel). Eluted DIC using
imidazole gradient was incubated with GST-PDZ and mutant GST-PDZ (AA) for
3 h at room temperature, washed four times with PBS and analysed.
Antibodies and dilutions for co-immunoprecipitation were: Shrm4 (1:100,
used as described in ref. 4), GFP (1:1,000, MBL International), and HA (1:1,000,
Invitrogen) (raised in rabbit); GABAB receptor 1 (1:2,000, Abcam), GABAAd
subunits (1:500, ROCKLAND), V5 (1:400, Invitrogen), and DIC (1:1,000, Abcam)
(raised in mouse).
Immunofluorescence and surface staining. Cultured hippocampal neurons
were fixed in 4% paraformaldehyde/4% sucrose for 10min at room temperature
and incubated in GDB1X solution (2 : gelatin 2%, Triton X-100 0.3%, 0.2 M
Na2HPO4 pH 7.4, 4 M NaCl) for 2 h at room temperature with primary antibodies:
Shrm4 (1:200, used previously4), synapsin 1 (1:200, SYnaptic SYstems) raised in
rabbit; b-Tubulin (1:10,000, Sigma), PSD-95 (1:400, NeuroMab), GluA2 (1:200,
NeuroMab), bassoon (1:100, Assay Designs), GABAB receptor 1 (directed against a
surface epitope, 1:200, Abcam), V5 (1:500, Invitrogen), myc (1:1,000, MBL
International), GABAA B3 (1:300, NeuroMab) (all raised in mice); Brevican (1:500,
BD Transduction Laboratories) raised in guinea pig. A similar protocol has been
used for dSTORM imaging.
For surface staining, live 18–20DIV hippocampal neurons were incubated
for 10min at 37 C with antibodies against GABABRs. After washing (PBS
supplemented with 1mM MgCl2 and 0.1mM CaCl2) neurons were fixed for
10min at room temperature in 4% paraformaldehyde/4% sucrose without
permeabilization. Coverslips were then washed, and incubated with Alexa 488
(1:400, Invitrogen), Alexa 555 (1:400, Invitrogen) or Cy5 (1:200, Jackson
Laboratories) secondary antibodies for 1 h at room temperature.
Colocalization analysis—Pearson correlation coefficient (r). Pearson correla-
tion coefficient (r) statistic was used to analyse the linear colocalization between
fluorophores using the JACoP plugin of ImageJ. For two directly interacting pro-
teins, the colocalization value of r tends towards 1. For high correlation, r is
between 0.5 and 1; medium correlation: 0.3 and 0.5; low correlation: 0.1 and 0.3.
Image acquisition. Confocal images were obtained as described previously72.
Briefly, fluorescence images were acquired with an LSM510 Meta confocal
microscope (Carl Zeiss; gift from F. Monzino) and a  63 objective (numerical
aperture 1.4) with sequential acquisition setting, at 1,280 1,024 pixels resolution.
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Image data were Z series projections of about 6–10 images, each averaged four
times and taken at depth intervals of 0.75 mm.
Quantification of GABABR fluorescence intensity. Images were quantified as
previously described in ref. 72. Images were acquired using a  63 objective and
average intensity of signals in proximal axon and primary dendrites were measured
in ImageJ. Brevican, a proteoglycan present in the growth cone was used to identify
the beginning of the axon and confirmed axonal identification. To prevent selection
bias during quantification, the axon and dendritic segments were selected in one
channel (GFP to visualization neuronal morphology) and quantified in the other
channel (GABABRs). A third channel was used to identified the axon (Brevican).
The axon and dendritic signals were measured in segments of the same size. To
control for background signals, we measured the intensity near the axon or
dendrite (same segment size) and subtracted the random fluorescence intensity in
these images. The average dendrite intensity Id and average axonal intensity Ia was
used to calculate the polarity index (PI) using PI¼ (Id Ia)/(Idþ Ia). For uniformly
distributed proteins Id¼ Ia and PI¼ 0, whereas PI40 or PIoindicates polarization
towards dendrites and axons, respectively30.
Calcium imaging and analysis. Ca2þ transients were imaged at 20Hz in Krebs
using GCaMP6 in hippocampal neurons transfected at 7DIV with scrambled,
Shrm4 knockdown and GABAB1DC constructs along with cDNAs for GCaMP6f
and dsRed. Fluorescence intensities (F) from ROIs, drawn around dendrites
were normalized to baseline fluorescence (F0) to obtain values of DF/F0. DF/F0
peaks were detected in Matlab using the Peakfinder plugin (Nathanael Yoder,
Mathworks). Ca2þ transients less than  3 the signal-to-noise ratio were excluded
from the analysis.
dSTORM and analyse of cross-correlation. Super-resolution localization
imaging was carried out by direct stochastic optical reconstruction microscopy
(dSTORM)73. Briefly, the fluorescent molecules of a sample prepared according to
a standard immunofluorescence protocol (see above) were induced to blink on and
off by modifying the chemical composition of the medium. If few molecules
fluoresce at a given time, such that the diffraction limited spots corresponding to
individual fluorophores are well separated, the position of each molecule can be
quantified with higher accuracy than the resolution limit74. By acquiring multiple
images of the same field (tens to hundreds of thousands), and storing the position
of the localized molecules at each frame it is therefore possible to obtain an image
of the sample with resolution higher than the diffraction limit. dSTORM was
performed on an optical setup based on a Leica SR GSD-3D (Leica Microsystems
Srl, Milan, Italy) super-resolution microscope equipped with a  160 1.43 NA
objective, an Andor iXon Ultra-897 EM-CCD sensor and three (405 nm 30mW,
488 nm 300mW and 642 nm 500mW) solid state lasers. The sample was mounted
on the stage and the medium was substituted before acquisition with a mix of
glucose oxidase (560mgml 1), caltalase (400 mgml 1) and Cysteamine HCl
(100mM) in TN buffer with 10% glucose w/v at pH 8 to induce blinking of the
fluorophores75. Alexa 647 and Atto 488 were imaged sequentially, starting from the
red channel. 30,000 images were collected for each channel with 5–20ms exposure
times and an increasing ramp of 405 nm laser intensity, with powers between 0 and
0.8mW, to reactivate the molecules in long-lived dark states. The super-resolution
images were reconstructed using the proprietary analysis software, discarding all
the detected events with less than 20 photons/pixel for Alexa 647 and 40 photons
for Atto 488. To quantify the co-clustering between the two labelled proteins,
the list of particles detected for each channel were used to compute the spatial
cross-correlation between the two signals76, using previously published routines
based on fast Fourier transformation written in Matlab77. Briefly flat cross-
correlation curves are representative of no co-clustering between the two labelled
proteins, while curves that significantly differ from 1 indicate that the two proteins
cluster together. For each condition, the cross-correlation was evaluated on B30
randomly chosen square regions of 2 mm sides. For visualization purposes, super-
resolution images were rendered as a 2D histograms with pixel sizes equal to
20 nm.
Y2H screening. For Y2H experiments, a fragment corresponding to the Shrm4
N-terminal PDZ domain (aa 1–91) was cloned in-frame with the GAL4 DNA-
binding domain of the pGBKT7 vector and used as bait to screen an adult human
brain cDNA library (Clontech, Mate and Plate Library). Positive yeast clones grew
on plates containing X-GAL and Aureobasidin A (QDO/X/A plates) and expressed
all four reporter genes: HIS3, ADE2, AUR1C and MEL1 under the control of three
distinct Gal4-responsive promoters. cDNA plasmids from positive clones were
recovered with the Easy Yeast plasmid isolation kit and transformed into DH5
E. coli grown on ampicillin plates, followed by sequencing.
Cell surface biotinylation assay. Hippocampal neuron membrane proteins were
biotinylated using membrane-impermeable sulfo-NHS-SS-biotin (0.3mgml 1,
Pierce) for 5min at 37 C. The neurons were then washed with tris-buffered saline
(TBS) supplemented with 0.1mM CaCl2, 1mMMgCl2 and 50mM glycine at 37 C,
and rinsed with TBS supplemented with 0.1mM CaCl2 and 1mM MgCl2 (without
glycine) on ice, followed by lysis in extraction buffer (50mM Tris–HCl, pH 7.4,
1mM EDTA, 150mM NaCl, 1% SDS, and protease inhibitors). Lysates were boiled
for 5min and biotinylated membrane proteins were precipitated with streptavidin-
conjugated beads (Dynabeads, Invitrogen). The beads were washed with lysis
buffer, boiled for 5min in sample buffer, filtered, and the proteins in solution
separated by SDS–PAGE for western blotting.
Live-cell internalization assay. GABABR internalization in live hippocampal
neurons was investigated as described previously78,79. Neurons at 14–21DIV
expressing GABABR heterodimers (R1a with bungarotoxin (BTX) binding site
along with R2) and either GFP-shRNA or GFP-scrambled-shRNA were incubated
in 1mM d-tubocurarine for 2min at room temperature followed by 3 mgml 1
BTX-AF555 (which attaches to the R1a binding site) for 10min at room
temperature. Receptor internalization was then followed as decay in surface
fluorescence at 30–32 C under the confocal microscope.
Live-cell imaging and FRAP. For live-cell imaging, neurons co-transfected with
GABAB1-RFP together with either GFP, Shrm4-shRNA or GFP-p150-cc1, were
placed in an incubator with imaging medium at 37 C and 5% CO2 mounted
on a Zeiss LSM510 Meta confocal microscope. Neurons expressing Shrm4-shRNA
or scrambled shRNA were imaged with the 458 nm laser; neurons expressing
GABAB1-mRFP were imaged with the 543 nm laser.
FRAP experiments were performed following Fossati et al.80 on GABAB1-RFP-
positive dendrites; regions of interest (ROI) on dendrites were defined and a
pre-bleaching image acquired at the start. The ROI was next bleached by scanning
30 times with 405 and 458 nm lasers until no fluorescence signal was detectable.
Fluorescence signal recovery was imaged over 10min, and normalized to the total
fluorescence of the pre-bleached ROI, which was verified as constant over time.
The images were analysed with ImageJ and the results analysed with Prism
(GraphPad).
Computational modelling. The structural models of GABAB1b and GABAB2 were
developed by comparative modelling using MODELLER81. We first modelled the
591–918 sequence GABAB1b, comprising the seven-helix bundle, the intracellular
and extracellular loops, and the C terminus up to the end of the coil–coil region
(879–918 sequence) by using the crystal structure of the metabotropic glutamate
receptor 5 (mGluR5; PDB 5CGC) as a template. One hundred models were
generated by randomizing all the Cartesian coordinates of standard residues in the
initial model. Extra-helical restraints were imposed to the following portions of the
receptor: 766–772 and 879–918, corresponding, respectively, to the N terminus of
helix 5 (H5) and the C terminal coil-coiled helix. In the model selected according
to a corroborated procedure82, the 887–918 portion of the C-terminal helix
was replaced with the corresponding helix from the crystallographic coil–coil
heterodimer (PDB: 4PAS). The best selected model of the GABAB1b served as
a template to build the seven-helix bundle and the loops of the GABAB2R. The
best model among the 100 produced was docked onto the structural model of
GABAB1bR following an already described procedure82. The receptor orientation
corresponding to an H1–H1, H7–H7 dimer, the most compatible with the C
terminal coil–coil heterodimer, was employed for model completion by adding the
C terminus. In this respect, the C-terminal helix was extracted from the
crystallographic heterodimer (PDB: 4PAS), whereas the segment connecting the
C-terminal end of H7 and the coil-coiled helix was built by means of the loop
routine in MODELLER.
The information from our in vitro experiments were employed to drive the
docking between the 859–870 GABAB1bR and the b2 strand of Shrm4-PDZ and
between the b1 strand of Shrm4-PDZ (PDB: 2EDP) and the 128–135 strand of IC2
in complex with dimeric LC8 of dynein (PDB: 2PG1). The two strands were docked
so as to form an extension of the antiparallel sheet between IC2 and LC8.
Injection of adeno-associated virus constructs. Five to seven-weeks-old male
Sprague Dawley rats, kept under 12 h light/dark conditions, with ad libitum
food and water, were anaesthetized with zoletil100 (0.1ml per 100 g) and xylazine
(0.1ml per 100 g) and secured in a Kopf stereotaxic frame. A cannula was inserted
into each CA1 (ref. 22). AAV5-shRNA#1 (or #2) or AAV5-scrambled shRNA#1
(or #2) (Penn Vector Core, University of Pennsylvania, USA) were injected directly
into the CA1 (coordinates AP:  3.8mm relative to Bregma; L: þ / 2mm; DV:
 2mm from skull; Paxinos and Watson, 1985) or into the Dentate Gyrus
(coordinates AP:  3.6mm relative to Bregma; L: 3.6þ / mm; DV:  3.5mm
from skull; Paxinos and Watson, 1985). Zoanthus sp. green fluorescence protein
was also incorporated into the AAV construct to report injection coordinates and
volumes. The animals were allowed to recover for 3 weeks before experimentation.
Whole-cell patch-clamp recording of GIRK currents. Current densities of G
protein-coupled inwardly rectifying Kþ (GIRK) channel conductance in response
to GABAB activation by baclofen, or mGluR activation by glutamate, were recorded
from hippocampal neurons in culture at 12–16DIV, using whole-cell patch-clamp
electrophysiology as described previously. Neurons were transfected at 7DIV with
shRNA, scrambled shRNA or the coiled-coil domain of dynactin (GFP-p150glued-
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cc1), and the cells were identified by their expression of GFP. Rescue experiments
were performed from neurons co-transfected at 7DIV with shRNA#1 and
HA-Shrm4 and the cells were identified by their expression of GFP. Patch pipettes
made of thin-walled borosilicate glass (outer diameter, 1.5mm; inner diameter,
1.17mm; GC-150TF-10; Harvard Apparatus, Kent, UK), (4–5MO) were filled with
internal solution (mM: 120 KCl, 2 MgCl2, 11 EGTA, 30 KOH, 10 HEPES, 1 CaCl2, 1
GTP, 2 ATP, pH 7.4). Neurons were continuously perfused with Krebs solution
(mM): 140 NaCl, 2.5 CaCl2, 4.7 KCl, 1.2 MgCl2, 11 glucose, and 5 HEPES, pH 7.4
and voltage-clamped at  70mV in whole-cell configuration, and series-resistance
compensation applied. Currents for 20 sweeps of  10mV hyperpolarising pulses
were recorded with an Axopatch 200B amplifier (Molecular Devices, CA, USA) at
10 kHz filtering. Similar sweeps were recorded at regular intervals after applying
series-resistance compensation of B40%. Cells were discarded in the event of a
change in series resistance 410%. To increase the size of GIRK currents and to
convert them to inward currents, before baclofen or glutamate application, the
KCl concentration was increased to 25mM and the NaCl concentration reduced to
120mM in the Krebs solution. This changed the EK from approximately  90 to
 47mV. In addition, 2mM kynurenic acid and 20 mM bicuculline were added
to the Krebs to block ionotropic glutamate and GABA receptors. Peak Kþ current
amplitudes were filtered at 5 kHz before storage for analysis with Clampex 10
software. Whole-cell capacitance was calculated using WinWCP V4.7 software
from the area under the membrane discharge curve from a clean averaged set of
 10mV hyperpolarizing pulses before applying compensation. Current density
was calculated by dividing the peak amplitude by the whole-cell capacitance.
Patch-clamp recordings of whole-cell mIPSCs. Whole-cell mIPSCs were
recorded in hippocampal neuron cultures at 14DIV after transfection with either
shRNA#1 or scrambled shRNA#1 at 8DIV. mIPSCs were recorded at a holding
potential of  70mV over 2-5min, filtered at 2 kHz and digitized at 20 kHz using
Clampex 10.1 software. Neurons were perfused with external solution (mM: 130
NaCl, 2.5 KCl, 2.2 CaCl2, 1.5 MgCl2, 10 D-glucose, 10 HEPES–NaOH, pH 7.4).
Sodium channel blocker (500 mM lidocaine) and NMDA, AMPA/kainate receptor
blocker (3mM kynurenic acid) were added to the external solution before
recording. The pipette solution was caesium chloride based (140 CsCl, 2 MgCl2, 1
CaCl2, 10 EGTA, 10 HEPES, 2 ATP (disodium salt) mM, adjusted to pH 7.3 with
CsOH). Recordings were performed with a Multiclamp 700B amplifier (Axon CNS
Molecular Devices, USA). Pipette resistance was 2–3MO and series resistance was
always below 20MO. Analyses were performed offline with pCLAMP 10.1 software
using a threshold crossing principle; the detection level was set at 5 pA. Raw data
were inspected visually to eliminate false events; data from cells with noisy or
unstable baselines were also discarded. mIPSC population averages were obtained
by aligning events at the mid-point of the rising phase.
Patch-clamp recordings on acute hippocampal slices. Adult (250–300 g)
male Sprague Dawley CD rats were used. The animals were injected with AAV5-
scrambled shRNA#1 (or #2) (left hemisphere) and AAV5-shRNA#1 (or #2)
(right hemisphere). Three weeks later the animals were anaesthetized in a chamber
saturated with chloroform and then decapitated. The brain was removed rapidly and
for patch-clamp recordings placed in ice-cold cutting solution (220mM sucrose,
2mM KCl, 1.3mM NaH2PO4, 12mMMgSO4, 0.2mM CaCl2, 10mM glucose, 3mM
kynurenic acid and 2.6mM NaHCO3, pH 7.3, perfused with 95% O2/5% CO2),
For recording fEPSPs, the brain was placed in oxygenated (95% O2/5% CO2) ice-
cold artificial CSF (aCSF; 125mM NaCl, 2.5mM KCl, 1.25mM NaH2PO4, 1mM
MgCl2, 2mM CaCl2, 25mM glucose, and 26mM NaHCO3, pH 7.3). Thickness of
300–400 mm coronal hippocampal slices were cut with a VT1000 S vibratome (Leica)
and incubated 40min at 36 C (patch-clamp) or room temperature (fEPSPs) in
aCSF. Slices were transferred to a recording chamber perfused with aCSF
(B2mlmin 1 at 32 C). Whole-cell patch-clamp and fEPSP recordings were
performed with a Multiclamp 700B amplifier (Axon CNS molecular devices, USA)
using an infrared-differential interference contrast microscope. Borosilicate glass
microelectrodes outer diameter 1.5mm (Sutter Instruments) were prepared with a
four-step horizontal puller (Sutter Instruments) and had a resistance of 3–5MO.
Whole-cell GABABR-mediated currents where recorded from CA1 pyramidal
neurons at a holding potential  80mV following perfusion of baclofen 100mM to
evoke GABABR currents and kynurenic acid (3mM) to block glutamatergic
transmission. At the end of each recording, the slices were perfused with GABABR
antagonist CGP55845 (5mM) to check current specificity. The pipettes were filled
with (126K gluconate, 4 NaCl, 1 EGTA, 1 MgSO4, 0.5 CaCl2, 3 ATP
(Mg salt), 0.1 GTP (Na salt), 10 glucose, 10 HEPES–KOHmM, pH 7.3).
fEPSPs were evoked by stimulation (frequency 0.05Hz) of the Schaffer
collateral pathway of the CA1 region using aCSF-filled monopolar glass pipettes.
fEPSPs were recorded (acquired at 20 kHz, filtered at 5 kHz) from the dendritic
field of CA1 pyramidal neurons again using aCSF-filled electrodes. Input–output
(I–O) curves were constructed by measuring the slope of fEPSPs evoked in
response to stimulation with increasing intensity (0–1.0mA). Stimulus strength
was adjusted to give 50% maximal response. Long-term potentiation was elicited by
high frequency stimulation (100 stimuli at 250Hz) while long-term depression was
elicited by low frequency stimulation (900 stimuli at 1Hz). Recordings were
acquired using Clampex 10.1 software and analysed offline with Clampfit 10.1
software.
For whole-cell patch-clamp electrophysiological recordings on dentate gyrus
granule cells, coronal hippocampal slices (thickness, 250–300 mm) were prepared
and incubated first for 40min at 36 C and then for 30min at room temperature in
oxygenated (95% O2/5% CO2). aCSF. Slices were transferred to a recording
chamber perfused with aCSF at 33 C temperature at a rate of about 2mlmin 1.
Tonic GABAergic currents and mIPSCs were recorded at a holding potential of
 65mV in the presence of kynurenic acid (3mM) with the caesium chloride
internal solution (above) supplemented with 5mM QX-314 (lidocaine N-ethyl
bromide, only for tonic currents).
Access resistance was between 10 and 20MO; if it changed by420% during the
recording, the recording was discarded. For tonic currents recordings, after a
baseline period of 2–5min, GABA (5 mM) or THIP (3 mM) was added to the aCSF
to increase the tonic component of the GABAergic transmission and to measure
modification in extrasynaptic GABAAR subunits composition. At the end of the
experiments bicuculline (20 mM) was added to block all GABAergic currents. For
the recording of mIPSCs, lidocaine (500 mM) was added in the external solution
and recordings were performed as previously described for culture experiments.
Analysis was performed offline with Clampfit 10.1 software. CPG 54628, the
selective GABABR antagonist, was used at the final concentration of 5 mM.
Behavioural tests. Behavioural tests were carried out 3 weeks after rats were
injected bilaterally with either Shrm4 AAV5-shRNA#1 (or #2) or AAV5-scrambled
shRNA#1 (or #2). The rats were maintained in 2 per cage post injections before
experiments were performed. Behavioural tests were carried out in the following
order with a gap of a week between tests: spontaneous motor activity, elevated plus
maze, marble-burying, EEG and PTZ-induced seizures. Ten animals per condition
were submitted to the behavioural tests for 3 consecutive weeks and during the
fourth and fifth weeks, animals of each condition were divided in two subgroups:
one submitted to PTZ-induced seizures and the other to EEG. Behavioural
experiments were carried out during the light phase of the light/dark cycle between
1000 hours and 1400 hours, and performed by trained observers blind to treatment.
Spontaneous motor activity test. Motor measurements were taken in
AAV5-shRNA#1 (or #2) or AAV5-scrambled shRNA#1 (or #2) bilaterally injected
rats. Spontaneous motor activity was evaluated as previously described83 in an
activity cage with the following dimensions: 43 cm long 43 cm wide 32 cm high
(Ugo Basile, Varese, Italy), placed in a sound attenuating room. The cage was
fitted with two parallel horizontal infrared beams 2 cm off the floor. Cumulative
horizontal movements were counted every 10min for 30.
Elevated plus maze test. The elevated plus maze procedure was used as
described previously84 to investigate anxiety-related behaviour in rats. The
apparatus consisted of two open arms (50 cm 10 cm) and two closed arms
(50 cm 10 cm 40 cm) at right angles, extending from a central platform
(10 cm 10 cm). The apparatus was placed 50 cm above the floor in the centre of a
small quiet room in dim light (about 30 lux). Testing was conducted during the
early light phase (0930–13.30 hours) of the cycle. After 20min adaptation to the
novel surroundings, an animal was placed on the central platform facing an open
arm. The number of open- and closed-arm entries, and time spent in open arms
were recorded over 5-min periods.
Marble-burying test. This test of anxiety was used according to ref. 85. The test
was conducted in a 43 cm 26 cm 22 cm box cage with 5 cm of fresh hardwood
chip bedding. Each animal was habituated for 15min to the cage. Then, an array of
24 standard marbles was arranged uniformly over the surface. Individual subjects
were placed again in the test cage for 15min. The number of marbles buried and
the latency to the first burying was recorded. A marble was scored as buried if more
than two-thirds of it was covered with sawdust. New bedding was used for each
animal and marbles were cleaned with 10% acetic acid solution between animals.
The same subjects were used for this test and in the elevated plus maze and were
tested in a counterbalanced order.
Sociability and social novelty test. Social behaviour was carried out in a three-
chamber apparatus according to Leite et al.85 The apparatus was an acrylic
rectangular box divided into three compartments of equal size (35 cm height, 50 cm
width, 50 cm deep) provided with doors. The sociability test was divided in three
sequential phases of 10min each. During the habituation period, the test rat was
placed in the middle chamber for 10min where the rat was free to explore the three
compartments. Each of the two sides contained an identical empty wire cage. In the
sociability phase, an unfamiliar rat (stranger 1) of the same strain, sex and weight
was enclosed in one of the wire cages and the time spent in each compartment with
the object or social stimulus was measured. In the social novelty phase, a new
unfamiliar rat (stranger 2) was enclosed into the wire cage in the opposite
compartment and the time spent in each compartment was measured. Before the
introduction of a social stimulus the test rat was trapped in the central chamber.
The test was videotaped and the time spent in each compartment was measured
offline.
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Tube test. The tube test is a well-known testing paradigm designed to measure
social hierarchies, and thus is relevant when investigating social dominance in
mice86 but it can be adapted to rats87. This test measures dominant/submissive
behaviour without allowing them to fight and injure each other. Rats were initially
habituated to the testing apparatus, which consisted of a 10 cm (diameter) by 50 cm
(length) transparent plastic tube, of sufficient size to allow one but not two rats to
move through the tube. Over two consecutive days, rats were allowed to run
through the tube on eight occasions, with alternate trials in which the entry and
exit ends were switched. Competition trials involved simultaneously releasing two
competing rats into opposite ends of the tube. The individual rat that was able to
travel forwards through the tube to exit the other side ‘won’ and was deemed
dominant; the rat that retreated was considered subordinate. The number of wins
(%) on the total number of competitions was measured.
Pentylenetetrazole-induced seizures. Animals (5 per condition) previously
injected (CA1) with AAV5-shRNA#1 or scrambled AAV5-shRNA#1, were injected
with pentylenetetrazole (45mg kg 1, i.p.) (Sigma, St. Louis, MO, USA). Seizures
was monitored for 30min after administration and rated on the Racine scale (1972)
(score: 0, no change; I, myoclonic jerks; II, minimum seizures, with convulsive
wave through body; III, fully-developed minimal seizures, clonus of head muscles
and forelimbs, righting reflex present; IV, major seizures (generalized without tonic
phase); V, generalized tonic-clonic seizures. The latency (s) to the first seizure and
total time spent in seizures (IV and V scale) were recorded.
Electroencephalogram recording. AAV5-scrambled#1 and AAV5-shRNA#1 rats
were anaesthetized with an i.p. injection of chloral hydrate dissolved in saline and
given at a volume of 10ml kg 1. Under anaesthesia (450mg kg 1, body weight
of chloral hydrate, i.p.; Sigma-Aldrich), all the rats were placed in a stereotaxic
instrument and four silver–silver chloride ball electrodes were fixed epidurally with
dental acrylic cement, as described in detail elsewhere88, on the right and left of the
parieto-occipital cortex according to the Paxinos and Watson brain atlas, 2mm
anterior, 2mm lateral from the midline and 3mm posterior from the bregma. The
four electrodes, and a fifth inserted into the nasal bone and used as ground,
were connected to a microconnector attached to the rat’s head with dental
cement (New Galetti e Rossi, Milan, Italy). Animals were treated with ceftriaxone
(50mg kg 1 i.p.) for three days. One week after electrode placement the rats
were allowed to acclimatize themselves to a sound-attenuated Faraday chamber
for 1 h a day for 3 days. Then, each freely moving awake rat was connected
to the microconnector. Signals were amplified by an Animal Bio-Amplifier
(AD Instruments), band-pass filtered (0.2–30Hz) and then connected to a PC for
signal acquisition (PowerLab system, AD Instruments, Castle Hill, Australia) at a
sampling rate of 100Hz and a resolution of 0.2Hz. Each animal was continuously
recorded for 24 h, under basal conditions. All collected data were analysed for
abnormalities by an experienced observer blinded to rat condition. All EEG traces
were scored for the presence of isolated spikes or repetitive spiking using an
additional software (LabChart v8 Pro Windows). Spikes were defined as having
a durationo200ms with baseline amplitude set to 4.5 times the standard deviation
of the EEG signal (determined during inter-spike activity periods, whereas
repetitive spiking activity was defined as three or more spikes lasting o5 s).
Immunohistochemistry. AAV-injected rats have been anesthetized with zoletil100
(0.1ml per 100 g) and xylazine (0.1ml per 100 g) and transcardially perfused with
PBS and PFA 4%/ Sucrose 4%. Dissected rat brains have been fixed ON in PFA 4%,
rinsed in PBS and cryoprotected with OCT. The blocks have been sectioned
(25 mm-thick) with a cryostat. Sections have been collected on glass slides, blocked
with 3% BSA,10% goat serum, 0.4% Triton in PBS for 1 h at RT and then incubated
with anti-PSD95 antibody (1:300 in blocking solution, Neuromab) at 4 C ON
followed by three washes with PBS. Sections have been incubated for 1 hr with the
secondary antibody (1:400, Alexa 555, Life Technlogies) at RT in blocking solution
and washed with PBS. Sections have been mounted on coated super-adhesive glass
slides and covered with Mowiol prior to confocal imaging. Images have been
deconvoluted with ImageJ plugin Iterative Deconvolve 3D.
Immuno-Electron Microscopy. Paraformaldehyde fixed neurons were incubated
with a polyclonal primary anti-Shrm4 diluted (1:100) in PBS containing 5% normal
goat serum, 0.1% saponin for 1 h; they were then incubated with a secondary
antibody conjugated with 1.4 nm gold particles (Life Technologies, CA, US) and
fixed with 1% glutaraldehyde in PBS. After washing, gold enhancement was
performed using the GoldEnhance EM 2113 kit (Nanoprobes, NY, US). Cells were
postfixed with 0.2% osmium tetroxide in 0.1 M phosphate buffer, stained with
0.25% uranyl acetate, dehydrated and embedded in epoxy resin. The distribution of
gold particles on ultrathin sections of cortical neurons was assessed adapting a
randomness test (Mayhew et al.,89). To evaluate the distribution of Shrm4 on our
sections, the following compartments were defined: synaptic boutons, post-synaptic
terminals, dendrites, un-determined structures and areas where cell structure is
absent.
Data availability. The authors declare that the data supporting the findings of this
study are available within the paper and its Supplementary Information files.
References
1. Hildebrand, J. D. & Soriano, P. Shroom, a PDZ domain-containing actin-
binding protein, is required for neural tube morphogenesis in mice. Cell 99,
485–497 (1999).
2. Hagens, O. et al. Disruptions of the novel KIAA1202 gene are associated with
X-linked mental retardation. Hum. Genet. 118, 578–590 (2006).
3. Taylor, J. et al. The scaffold protein POSH regulates axon outgrowth. Mol. Biol.
Cell 19, 5181–5192 (2008).
4. Yoder, M. & Hildebrand, J. D. Shroom4 (Kiaa1202) is an actin-associated
protein implicated in cytoskeletal organization. Cell Motil. Cytoskeleton 64,
49–63 (2007).
5. Honda, S. et al. Copy-number variations on the X chromosome in Japanese
patients with retardation detected by array-based comparative genomic
hybridization analysis. J. Hum. Genet. 55, 590–599 (2010).
6. Nizon, M. et al. Phenotype-genotype correlations in 17 new patients with an
Xp11.23p11.22 microduplication and review of the literature. Am. J. Med.
Genet. 167A, 111–122 (2014).
7. Armanet, N. et al. Double Xp11.22 deletion including SHROOM4 and CLCN5
associated with severe psychomotor retardation and Dent disease. Mol.
Cytogenet. 8, 8 (2015).
8. Lopes, F. et al. Identification of novel genetic causes of Rett syndrome-like
phenotypes. J. Med. Genet. 53, 19–19 (2016).
9. Srivastava, S. et al. A novel variant in GABRB2 associated with intellectual
disability and epilepsy. Am. J. Med. Genet. 164A, 2914–2921 (2014).
10. Yuan, H. et al. Ionotropic GABA and Glutamate receptor mutations and
human neurologic diseases. Mol. Pharmacol. 88, 203–217 (2015).
11. Luscher, B., Fuchs, T. & Kilpatrick, C. L. GABAA receptor trafficking-mediated
plasticity of inhibitory synapses. Neuron 70, 385–409 (2011).
12. Gassmann, M. & Bettler, B. Regulation of neuronal GABA(B) receptor
functions by subunit composition. Nat. Rev. Neurosci. 13, 380–394 (2012).
13. Moss, S. J. & Smart, T. G. Constructing inhibitory synapses. Nat. Rev. Neurosci.
2, 240–250 (2001).
14. Bettler, B., Kaupmann, K., Mosbacher, J. & Gassmann, M. Molecular structure
and physiological functions of GABA(B) receptors. Physiol. Rev. 84, 835–867
(2004).
15. Rudolph, U. & Mohler, H. GABAA receptor subtypes: Therapeutic potential in
Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev.
Pharmacol. Toxicol. 54, 483–507 (2014).
16. Watanabe, M. et al. GABA and GABA receptors in the central nervous system
and other organs. Int. Rev. Cytol. 213, 1–47 (2002).
17. Bartoi, T. et al. GABAB receptor constituents revealed by tandem affinity
purification from transgenic mice. J. Biol. Chem. 285, 20625–20633 (2010).
18. Sengupta, P. et al. Probing protein heterogeneity in the plasma membrane using
PALM and pair correlation analysis. Nat. Methods 8, 969–975 (2011).
19. Calver, A. R. et al. The C-terminal domains of the GABA(b) receptor subunits
mediate intracellular trafficking but are not required for receptor signaling.
J. Neurosci. 21, 1203–1210 (2001).
20. Pagano, A. et al. C-terminal interaction is essential for surface trafficking but
not for heteromeric assembly of GABA(b) receptors. J. Neurosci. 21, 1189–1202
(2001).
21. Sala, C. & Segal, M. Dendritic spines: the locus of structural and functional
plasticity. Physiol. Rev. 94, 141–188 (2014).
22. Cuny, H. et al. gamma-Aminobutyric acid type B (GABAB) receptor expression
is needed for inhibition of N-type (Cav2.2) calcium channels by analgesic
alpha-conotoxins. J. Biol. Chem. 287, 23948–23957 (2012).
23. Hannan, S. et al. Gamma-aminobutyric acid type B (GABA(B)) receptor
internalization is regulated by the R2 subunit. J. Biol. Chem. 286, 24324–24335
(2011).
24. Hirokawa, N., Noda, Y. & Okada, Y. Kinesin and dynein superfamily
proteins in organelle transport and cell division. Curr. Opin. Cell Biol. 10, 60–73
(1998).
25. Valdes, V. et al. Endoplasmic reticulum sorting and kinesin-1 command the
targeting of axonal GABAB receptors. PLoS ONE 7, e44168 (2012).
26. Valenzuela, J. I. et al. Transport along the dendritic endoplasmic reticulum
defines the trafficking modality for GABAB receptors. J. Cell Sci. 127,
3382–3395 (2014).
27. Raimondi, F. et al. A mixed protein structure networl and elastic network
model approach to predict the structural communication in biomolecular
systems: the PDZ2 domain from tyrosine phosphatase 1E as a case study.
J. Chem. Theory Comput. 9, 2504–2518 (2013).
28. Burmakina, S. et al. Heterodimeric coiled-coil interactions of human GABAB
receptor. Proc. Natl Acad. Sci. USA 111, 6958–6963 (2014).
29. Zheng, Y. et al. Dynein is required for polarized dendritic transport
and uniform microtubule orientation in axons. Nat. Cell Biol. 10, 1172–1180
(2008).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14536 ARTICLE
NATURE COMMUNICATIONS | 8:14536 | DOI: 10.1038/ncomms14536 | www.nature.com/naturecommunications 15
30. van Spronsen, M. et al. TRAK/Milton motor-adaptor proteins steer
mitochondrial trafficking to axons and dendrites. Neuron 77, 485–502 (2013).
31. Vigot, R. et al. Differential compartmentalization and distinct functions of
GABAB receptor variants. Neuron 50, 589–601 (2006).
32. Margeta-Mitrovic, M. et al. A trafficking checkpoint controls GABA(B)
receptor heterodimerization. Neuron 27, 97–106 (2000).
33. Luscher, C., Jan, L. Y., Stoffel, M., Malenka, R. C. & Nicoll, R. A. G protein-
coupled inwardly rectifying Kþ channels (GIRKs) mediate postsynaptic but
not presynaptic transmitter actions in hippocampal neurons. Neuron 19,
687–695 (1997).
34. Stell, B. M., Brickley, S. G., Tang, C. Y., Farrant, M. & Mody, I. Neuroactive
steroids reduce neuronal excitability by selectively enhancing tonic inhibition
mediated by delta subunit-containing GABAA receptors. Proc. Natl Acad. Sci.
USA 100, 14439–14444 (2003).
35. Tao, W., Higgs, M. H., Spain, W. J. & Ransom, C. B. Postsynaptic GABAB
receptors enhance extrasynaptic GABAA receptor function in dentate gyrus
granule cells. J. Neurosci. 33, 3738–3743 (2013).
36. Connelly, W. M. et al. GABAB Receptors Regulate Extrasynaptic GABAA
Receptors. J. Neurosci. 33, 3780–3785 (2013).
37. Farrant, M. & Nusser, Z. Variations on an inhibitory theme: phasic
and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 6, 215–229
(2005).
38. Pilc, A. & Nowak, G. GABAergic hypotheses of anxiety and depression: focus
on GABA-B receptors. Drugs Today 41, 755–766 (2005).
39. Gambardella, A. et al. GABA(B) receptor 1 polymorphism (G1465A) is
associated with temporal lobe epilepsy. Neurology 60, 560–563 (2003).
40. Ramamoorthi, K. & Lin, Y. The contribution of GABAergic dysfunction to
neurodevelopmental disorders. Trends Mol. Med. 8, 452–462 (2011).
41. Nakamura, T. et al. PX-RICS-deficient mice mimic autism spectru disorder in
Jacobsen through impaired GABAA receptor trafficking. Nat. Commun. 7,
10861 (2016).
42. Silverman, J. L. et al. GABAB receptor agonist R-Baclofen reverses social
deficits and reduces repetitive behavior in two mouse models of autism.
Neuropsychopharmacology 40, 2228–2239 (2015).
43. Jacobson, L. H., Bettler, B., Kaupmann, K. & Cryan, J. F. Behavioral evaluation
of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned
anxiety. Psychopharmacology 190, 541–553 (2007).
44. Leite, I. S., Castelhano, A. S. & Cysneiros, R. M. Effect of diazepam on
sociability of rats submitted to neonatal seizures. Data Brief 7, 686–691 (2016).
45. Lindzey, G., Winston, H. & Manosevitz, M. Social dominance in inbred mouse
strains. Nature 191, 474–476 (1961).
46. Kong, W. L. et al. Role of TRPV1 in susceptibility to PTZ-induced seizure
following repeated hyperthermia challenges in neonatal mice. Epilepsy Behav.
31, 276–280 (2014).
47. Obiak, A. L., Gibbs, T. T. & Blatt, G. J. Decreased GABA(B) receptors in the
cingulate cortex and fusiform gyrus in autism. J. Neurochem. 114, 1414–1423
(2010).
48. Fatemi, S. H. et al. Expression of GABA(B) receptors is altered in brains of
subject with autism. Cerebellum 8, 64–69 (2009).
49. Pacey, L. K., Heximer, S. P. & Hampson, D. R. Increased GABA(B) receptor-
mediated signaling reduces the susceptibility of fragile X knockout mice to
audiogenic seizures. Mol. Pharmacol. 76, 18–24 (2009).
50. Oberman, L. M. mGluR antagonists and GABA agonists as novel
pharmacological agents for the treatment of autism spectrum disorders. Expert
Opin. Investig. Drugs 21, 1819–1825 (2012).
51. Berry-Kravis, E. M. et al. Effects of STX209 (arbaclofen) on neurobehavioral
function in children and adults with fragile X syndrome: a randomized,
controlled, phase 2 trial. Sci. Transl. Med. 4, 152ra127 (2012).
52. Cellot, G. & Cherubini, E. GABAergic signaling as therapeutic target for autism
spectrum disorders. Front. Pediatr. 2, 70 (2014).
53. Balasubramanian, S., Fam, S. R. & Hall, R. A. GABAB receptor association with
the PDZ scaffold Mupp1 alters receptor stability and function. J. Biol. Chem.
282, 4162–4171 (2007).
54. Biermann, B. et al. The Sushi domains of GABAB receptors function as axonal
targeting signals. J. Neurosci. 30, 1385–1394 (2010).
55. Kunde, S. A. et al. The X-chromosome-linked intellectual disability protein
PQBP1 is a component of neuronal RNA granules and regulates the appearance
of stress granules. Hum. Mol. Genet. 20, 4916–4931 (2011).
56. Schuler, V. et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre- and
postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 31,
47–58 (2001).
57. Signorini, S., Liao, Y. J., Duncan, S. A., Jan, L. Y. & Stoffel, M. Normal cerebellar
development but susceptibility to seizures in mice lacking G protein-coupled,
inwardly rectifying Kþ channel GIRK2. Proc. Natl Acad. Sci. USA 94, 923–927
(1997).
58. Mombereau, C., Kaupmann, K., van der Putten, H. & Cryan, J. F. Altered
response to benzodiazepine anxiolytics in mice lacking GABA B(1) receptors.
Eur. J. Pharmacol. 497, 119–120 (2004).
59. Kulik, A. et al. Subcellular localization of metabotropic GABA(B) receptor
subunits GABA(B1a/b) and GABA(B2) in the rat hippocampus. J. Neurosci. 23,
11026–11035 (2003).
60. Wei, W., Zhang, N., Peng, Z., Houser, C. R. & Mody, I. Perisynaptic
localization of delta subunit-containing GABA(A) receptors and their
activation by GABA spillover in the mouse dentate gyrus. J. Neurosci. 23,
10650–10661 (2003).
61. Spigelman, I. et al. Behavior and physiology of mice lacking the GABAA-
receptor delta subunit. Epilepsia 43, 3–8 (2002).
62. Bassani, S. et al. The neurobiology of X-linked intellectual disability.
Neuroscientist 19, 541–552 (2013).
63. Rex, C. S. et al. Myosin IIb regulates actin dynamics during synaptic plasticity
and memory formation. Neuron 67, 603–617 (2010).
64. Kim, I. H. et al. Disruption of Arp2/3 results in asymmetric structural plasticity
of dendritic spines and progressive synaptic and behavioral abnormalities.
J. Neurosci. 33, 6081–6092 (2013).
65. Chalifoux, J. R. & Carter, A. G. GABAB receptors modulate NMDA receptor
calcium signals in dendritic spines. Neuron 66, 101–113 (2010).
66. Stanic, J. et al. Rabphilin 3A retains NMDA receptors at synaptic sites
through interaction with GluN2A/PSD-95 complex. Nat. Commun. 6, 10181
(2015).
67. Taylor, J. et al. The scaffold protein POSH regulates axon outgrowth. Mol. Biol.
Cell 19, 5181–5192 (2008).
68. Valnegri, P. et al. The X-linked intellectual disability protein IL1RAPL1
regulates excitatory synapse formation by binding PTPd and RhoGAP2. Hum.
Mol. Genet. 20, 4797–4809 (2011).
69. Folci, A. et al. Loss of hnRNP K impairs synaptic plasticity in hippocampal
neurons. J. Neurosci. 34, 9088–9095 (2014).
70. Niclas, J. et al. Closing and localization of a conventional kinesin motor
expressed exclusively in neurons. Neuron 12, 1059–1072 (1994).
71. Lois, C., Hong, E. J., Pease, S., Brown, E. J. & Baltimore, D. Germline
transmission and tissue-specific expression of transgenes delivered by lentiviral
vectors. Science 295, 868–872 (2002).
72. Bassani, S. et al. The X-linked intellectual disability protein TSPAN7 regulates
excitatory synapse development and AMPAR trafficking. Neuron 73,
1143–1158 (2012).
73. Heilemann, M. et al. Subdiffraction-resolution fluorescence imaging with
conventional fluorescent probes. Angew. Chem. 47, 6172–6176 (2008).
74. Thompson, R. B. & McVeigh, E. R. High temporal resolution phase
contrast MRI with multiecho acquisitions. Magn. Reson. Med. 47, 499–512
(2002).
75. Dempsey, G. T., Vaughan, J. C., Chen, K. H., Bates, M. & Zhuang, X. Evaluation
of fluorophores for optimal performance in localization-based super-resolution
imaging. Nat. Methods 8, 1027–1036 (2011).
76. Sengupta, P. et al. Probing protein heterogeneity in the plasma membrane using
PALM and pair correlation analysis. Nat. Methods 8, 969–975 (2011).
77. Veatch, S. L. et al. Correlation functions quantify super-resolution images and
estimate apparent clustering due to over-counting. PLoS ONE 7, e31457
ð2012Þ:
78. Hannan, S., Wilkins, M. E. & Smart, T. G. Sushi domains confer distinct
trafficking profiles on GABAB receptors. Proc. Natl Acad. Sci. USA 109,
12171–12176 (2012).
79. Hannan, S., Wilkins, M. E., Thomas, P. & Smart, T. G. Tracking cell surface
mobility of GPCRs using alpha-bungarotoxin-linked fluorophores. Methods
Enzymol. 521, 109–129 (2013).
80. Fossati, M., Colombo, S. F. & Borgese, N. A positive signal prevents secretory
membrane cargo from recycling between the Golgi and the ER. EMBO J. 33,
2080–2097 (2014).
81. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of
spatial restraints. J. Mol. Biol. 234, 779–815 (1993).
82. Fanelli, F. Modeling the structural communication in supramolecular
complexes involving GPCRs. Methods Mol. Biol. 914, 319–336 (2012).
83. Braida, D., Pozzi, M., Cavallini, R. & Sala, M. 3,4 methylenedioxymetham-
phetamine (ecstasy) impairs eight-arm radial maze performance and arm entry
pattern in rats. Behav. Neurosci. 116, 298–304 (2002).
84. Braida, D. et al. Diazepam protects against the enhanced toxicity of cocaine
adulterated with atropine. J. Pharmacol. Sci. 107, 408–418 (2008).
85. Leite, I. S., Castelhano, A. S. & Cysneiros, R. M. Effect of diazepam
on sociability of rats submitted to neonatal seizures. Data Brief 7, 686–691
(2016).
86. Lindzey, G., Winston, H. & Manosevitz, M. Social dominance in inbred mouse
strains. Nature 191, 474–476 (1961).
87. Jupp, B. et al. Social dominance in rats: effects on cocaine self-administration,
novelty reactivity and dopamine receptor binding and content in the striatum.
Psychopharmacology 233, 579–589 (2016).
88. Sala, M. E. et al. EEG power spectra and behavioral correlates in rats given
chronic morphine. Lack of residual long-term EEG and neuronal changes.
Pharmacol. Res. 32, 95–103 (1995).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14536
16 NATURE COMMUNICATIONS | 8:14536 | DOI: 10.1038/ncomms14536 | www.nature.com/naturecommunications
89. Mayhew, T. M. et al. Relative labelling index: a novel stereological approach to
test for non-random immunogold labeling of organelles and membranes on
transmission electron microscopy thin sections. J. Microsc. 205, 153–164 (2002).
Acknowledgements
We thank Don Ward for language assistance. J.Z. and C.H. were supported by
Marie Curie Actions; SyMBaD programme. M.P. was supported by Telethon Italy
(TDMP11611TC), (GGP12097), (GGP15167A) and Fondation Lejeune. L.P. was
supported by Fondazione Umberto Veronesi, Milan. B.B. was supported by the
Swiss National Science Foundation (31003A-152970). C.S. was supported by Telethon
(GGP11095), Ministry of Health in the frame of ERA-NET NEURON and PNR-CNR
Aging Programme 2012–2014. M.P. and C.S. were supported by Fondazione CARIPLO
(Project No. 2012-0593). S.H. and T.G.S. were funded by the Medical Research Council
U.K., The Rosetrees Trust and the Leverhulme Trust.
Author contributions
J.Z., E.M. and M.P. conceived the original idea and wrote the manuscript. J.Z. and E.M.
designed and performed the majority of the experiments. S.H. and L.M. designed and
performed electrophysiological experiments. A.L., C.H. and P.V. designed and
perfomed biochemical experiments. D.M. designed and performed dSTORM
experiments. L.B. designed and performed electron microscopy experiments. M.F.
designed and performed time-lapse experiment. L.P. and D.B. designed and performed
behavioural tests. M.S., M.F., J.H., V.K., F.F., C.S., B.B., S.B. and T.G.S. provided useful
comments and review the manuscript. M.P. coordinated the entire project and obtained
the main source of fundings.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial
interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Zapata, J. et al. Epilepsy and intellectual disability linked protein
Shrm4 interaction with GABABRs shapes inhibitory neurotransmission. Nat. Commun.
8, 14536 doi: 10.1038/ncomms14536 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14536 ARTICLE
NATURE COMMUNICATIONS | 8:14536 | DOI: 10.1038/ncomms14536 | www.nature.com/naturecommunications 17
